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Herpes Simplex Virus Type 1 (HSV-1) represents an attractive vehicle for a variety of 
gene therapy applications.  To render this virus safe for clinical use, its cytotoxic genes must be 
removed without losing its ability to express transgenes efficiently.  Therefore, complementing 
cell lines that can provide high titer virus are essential for clinical application.  Manufacturing 
methods that can purify these vectors of host cell DNA and protein are also necessary for 
translation of this gene therapy strategy into clinic.  
In this thesis, I have developed complementing cell lines that allow propagation to up to 
1E6 PFU/ml routinely for triple as well as quadruple deleted vectors which are among the most 
difficult to culture to high titer.  Replacement of the ICP4 promoter with the VP16 enhancer 
element enriched ICP0 IE gene promoter resulted in higher induction levels and faster kinetics of 
ICP4 expression and a 10 fold increase in vector yield. 
Along these lines, I investigated the repressive nature of Vero cells to a quadruple IE 
mutant.  A high throughput cell based chemical screen revealed a metal chelator, 1 10 
phenanthroline, that was able to derepress EGFP expression not only from the quadruple 
backbone but of other ICP0 mutant viruses suggesting a unique cell state that was permissive for 
HSV-1 transgene expression.  Interestingly, proteosome inhibition studies reveal that this 
pathway is essential for this effect not only in Vero cells but also normally permissive U2OS 
cells.  
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 Finally, a systematic study into ion exchange chromatography for purification of these 
vectors reveals dramatic differences in infectious yield depending on the matrix chosen.  Anion 
exchange resins bound the virus with high affinity and require high salt concentrations to recover 
adequate titers.  Cation exchange chromatography was able to purify HSV-1 to moderate titers 
while removing a majority of the host contaminating DNA and protein in accordance with FDA 
standards for clinical grade viral based vaccines. 
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1.0  INTRODUCTION 
Viral based gene therapy vectors have long been an active area of research owing to their 
different tissue tropisms and efficient method of gene delivery.  One caveat that has complicated 
this technique is the issue of safety.  Since most viruses are pathogenic they need to be made safe 
for clinical use and this is done through the construction of replication defective viruses.  
Replication defective viruses are constructed in a way that the essential gene functions are 
missing so as to block replication and therefore a major pathogenic effect once inside the host.  
Another barrier to clinic is the issue of scale of manufacture.  Large scale production of  
replication defective vectors remains challenge on both the upstream and downstream sides.  
Historically, these replication defective vectors, which also include vaccines, are manufactured 
through the use of packaging cell lines that provide missing functions in trans. Generation of  
stable complementing cell lines remains a challenge since the products they conditionally 
express are normally quite toxic to the cell.  Additionally, these products must be expressed with 
adequate kinetics and levels that mirror a normal wild type infection.  Compounded with these 
issues are the stringent requirements imposed by the FDA for product purity (contaminating 
cellular DNA and protein) and lot to lot variability.  Purification of viral based products is a 
relatively new field, but recent advances have revealed major breakthroughs in downstream 
processing of these vectors which include optimized size exclusion and ion exchange 
chromatography processes for different viral strains. 
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1.1 BACKGROUND 
1.1.1 Gene Therapy 
With the advent of the human genome project and recent advances in stem cell 
technology, the field of gene therapy is destined to become a frontrunner for new treatments of 
life threatening diseases.  Gene therapy is traditionally defined as the transfer of genetic material 
either from a virus, naked DNA or RNA, or liposomes to treat a certain disease state.  Gene 
therapy has the advantage of delivering the precise gene product to the particular disease state 
while taking advantage of the viral immune evasion mechanisms in vivo.  Viruses are naturally 
derived vehicles that offer the advantage of tissue tropism as well as large genetic payload.   
Typically, gene therapy works well for providing a single missing gene function as is the case 
with parkinson’s, cystic fibrosis, or muscular dystrophy.  However, recent work has shown that 
other avenues can be explored such as chronic pain, bone regeneration, oxidative injury, and 
cancer therapy.  The incorporation of gene therapy as an adjunct therapy is becoming more 
common place and may serve more utility than as an alternative to current approaches (4, 70, 
145).   
 
For gene therapy to be successful, a few criteria must be met.  (1) There must be a suitable 
disease model, (74) specific delivery to the disease state, (2) efficient gene transduction with 
suitable kinetics, and (3) limited toxicity in vivo.  Commonly the rate limiting step for these 
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criteria is effectively targeting the specific malady within a myriad of cellular receptors while 
minimizing toxic effects to normal tissue.  Recent efforts have shown that retargeting of viral 
vectors is possible through genetic modification of the nucleocapsid and glycoprotein coat of 
different viruses mainly for cancer therapy (94, 119, 190).  Removal of toxicity is commonly 
carried out by deleting essential gene functions that allow viral replication and therefore halting 
any pathogenic effect at the level of entry.  These vectors, termed replication defective, exhibit 
reduced toxicity and enhanced gene transduction in a wide range of  tissue types (15, 31, 77, 93).  
In addition to the aforementioned limitations to gene therapy is the issue of efficient 
manufacturing processes for well defined gene therapy products that are suitable for clinical 
trials.  There have been many recent advances in the field of gene therapy vector production 
(133, 134).  Once these processes have been optimized for efficient large scale manufacture the 
full potential of gene therapy can be realized.    
1.1.2 Gene Therapy Vectors 
Gene transduction is the method of expressing an ectopic gene in a particular tissue.  The success 
of this process relies on efficient delivery and stable expression.  The vector itself serves to (i) 
deliver the genetic payload to the desired tissue and (ii) protect the genes from degradation by 
host immune surveillance.  An ideal vector should be able to efficiently deliver the genetic 
material as well as avoid any pathogenicity.  Additionally, these vectors must be able to be 
produced at high concentration easily.  With the wide variety of disease models available it is 
clear that there is no universal method of delivery that is suitable for all applications.  Vector 
mediated gene transfer can be carried out by one of two ways either viral or non-viral.   
Most non-viral methods are composed of synthetic carriers such as liposomes, polyplexes, 
nanoparticles, or alternatively naked DNA injection.  Naked DNA injection has worked well in 
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the case of muscle transduction since there are low levels of nuclease activity (5).  However, 
systemic injection suffers from the presence of serum nucleases that can clear the foreign DNA 
within minutes (78). Synthetic carrier methods are attractive from the standpoint of toxicity since 
there is little immune response to most of the cationic polymers used to house DNA.  These 
polymers consist of positively charged repeating monomers that are tailored to bind to cell 
surface receptors in vivo.  In addition to protection of the genetic material, the polymers chosen 
can interact with multiple biologic interfaces within the cell to alter the functionality of the 
carrier.  Some examples of the systems chosen for liposomal delivery are poly-L-lysine and 
polyethylene glycol that have attractive biocompatibility profiles and suitable clearance rates 
(35).  An active area of research is polymer design to complex foreign DNA that can be targeted 
to specific tissue types.  Lipoplexes with DNA offer the advantage of higher order interactions 
through multi lamellar complexes (79).  As the DNA condenses around positively charged head 
groups different lipid layers can be formed and tightly controlled to specifically interact with 
different subcellular components.  Some of the major hurdles this technology still faces are 
endosomal escape and nuclear transport.  One other limitation to these synthetic systems is the 
lack of an ideal cationic lipid since there are no general correlations with structure and function 
in vivo.  In addition, correlations between in vitro and in vivo work remains unclear complicating 
development in this delivery method due to the presence of multiple interaction possibilities 
within the bloodstream (161).  Even with these limitations, this delivery method will no doubt 
with experience and understanding rival that of the viral based gene therapy due to the tunable 
nature of synthetic polymers and their attractive biocompatibility profiles. 
Viral based gene delivery methods benefit from natural tissue tropisms and exploitation of the 
host cell machinery to amplify the exogenous DNA.  Gene therapy based on a broad range of 
viruses has been the focus of many institutions and each vector system has their own intrinsic 
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limitations and advantages.  Table 1 shows the current state of the art in regard to virus based 
gene therapies and their use in clinical trials dating from 1989 to the present. 
Table 1. Virus Based Gene Therapy Clinical Trials (102) 
Virus Genetic Material Genetic Payload  
Capacity 
Percentage of Clinical 
Trials 
Adenovirus dsDNA < 5kb (n=331)  36.65% 
Retrovirus RNA < 8 kb (n=305) 33.77% 
Vaccinia dsDNA 25 kb (n=91) 10.07% 
Pox Virus dsDNA 25 kb (n=86) 9.52% 
Adeno Associated Virus ssDNA 5 kb (n=47) 5.2% 
Herpes Simplex Virus dsDNA 40 kb (n=43) 4.76% 
 
All of these viruses are rendered therapeutic by insertion of foreign DNA into the viral 
genome in place of a toxic viral gene while leaving the cis acting elements intact such as origins 
of replication and packaging signals.  These deleted genes usually comprise immediate early 
genes, replication machinery, or nonessential structural components. 
1.1.2.1 Retrovirus 
Most retroviral vectors are based on the  betaretrovirus Murine Moloney Leukemia Virus 
(MMLV).  The MMLV genome encodes for three essential genes: gag, pol, and env.  The env 
gene is cleaved within the trans-Golgi network to produce transmembrane and surface unit 
subunits interacts with cell surface receptors to allow binding of the virus on the target cell.  
Once inside the cell, the virus is uncoated and the RNA is reverse-transcribed into proviral 
double stranded DNA by the pol gene and subsequently transported to the nucleus for 
integration.  All that is required for viral replication in cis are the 3’ and 5’ long terminal repeats 
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(LTRs), which house the sites of DNA transcription initiation and polyadenylation.  These sites 
are essential for production of progeny viral genomes and viral mRNA.  A packaging signal 
termed psi is also located near the 5’ repeat sequence which directs incorporation of viral DNA 
into the capsid.  As the viral DNA is packaged, the gag gene directly binds to the viral RNA to 
promote packaging into the virion.  Retroviral vectors are typically propagated on murine based 
cell lines that provide the missing essential genes in trans.  These cell lines have been recently 
developed to contain the env, gag, and pol genes on separate plasmids to reduce the possibility of 
generating replication competent retroviral vectors (107, 115).  Sequence homology limitation is 
another strategy used to minimize recombination events between the gene supplied in trans and 
the deleted virus.  In addition, suspension cell lines are being developed for the use of large scale 
manufacture of recombinant retroviral vectors (143).  Downstream processing and concentration 
of retroviral particles is often difficult due to the fragile nature of the virus (32).  Step-wise 
filtration can be used to purify these vectors but can be clone specific resulting in titer 
improvements from 2-10 fold (141).  Recently, ion exchange chromatography through the use of 
a weak anion exchange matrix allowed superior recovery while minimizing contaminating 
cellular debris and DNA (146).  
For most types of retroviruses, mitosis is required to integrate into the host genome which 
remains a limitation to the development of this as a system for gene therapy.  This stable 
integration contrasts with other viral DNA vectors such as herpes simplex virus and adenovirus 
where the genome remains episomal.  The main drawback to this system of gene transfer is the 
issue of insertional activation.  A recent French trial for severe combined immunodeficiency 
(SCID) resulted in a fatality due to induced expression of lmo2 which is abnormally expressed in 
childhood acute lymphoblastic leukemia (73).  These safety concerns have severely limited the 
number of funded studies using retroviral systems and resulted in a recommendation from the 
NIH that this vector system be used in extreme cases (54). 
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 1.1.2.2 Adenovirus 
Adenovirus is a double stranded DNA virus that is the focus of a wide variety of gene 
therapy strategies ranging from oncolytic treatment of glioma to cystic fibrosis.  Structurally, the 
virus is around 200 nm in diameter with the viral capsid extended by fibers with distal knobs that 
interact with specific host cell receptors.  Currently there are approximately 50 serotypes of 
adenovirus with group C being the most studied which contains serotypes 1, 2, 5, and 6.  
Adenovirus serotype 5 is the prototypical vector used for gene therapy. The 36 kb genome is 
flanked at the termini by inverted repeats that each contains an origin of replication and a 
terminal protein binding site.  Unique to this virus and hepadnaviruses is the mechanism of 
protein primed viral DNA replication in which the viral encoded proteins preterminal protein and 
DNA polymerase attach at the 3’ end in association with other cellular factors (Nf-1 and Oct-1) 
to form a preinitiation complex.  The genomic replication occurs continuously through strand 
displacement.  Much like other DNA viruses, the gene expression of adenovirus occurs in a 
temporally regulated cascade with the immediate early gene, E1A, serving as the major 
transactivator.  This gene is commonly removed to generate replication defective vectors and 
supplied in trans in complementing cell lines to propagate viral vectors.  As with other 
replication defective vectors, generation of recombinant replication competent vectors during 
large scale production is a major source of concern. Further deletion of the E2 region of the 
genome, which contains both the preterminal protein and DNA polymerase, attenuates the 
toxicity of these vectors but efforts to complement in trans have shown that this gene product 
may be limiting for efficient  replication defective adenoviral production (208, 209).  Using this 
production strategy viral titers up to 109 pfu/ml to 1012 transducing units/ml have been reported 
making this virus a popular choice on the basis of scaleable production (167). 
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Since transgene expression from adenoviral vectors is temporary, the host immune 
response is a major limitation for application into clinic (200, 201).  Another limitation is the 
generation of a humoral response against this vector which may limit repeated administration 
(104).  However, the knob region of the fiber rods of adenovirus can be modified to pseudotype 
gene therapy vectors such that retargeting to different tissue types and possible circumvention of 
the immune response can occur (188).  Since long term transgene expression is not feasible with 
this vector type, the future of adenovirus gene therapy may be more amenable to diseases that 
require transient gene expression and vaccine generation.  
1.1.2.3 AdenoAssociated Virus 
Adeno associated virus is a parvovirus that requires the aid of helper virus such as 
adenovirus or herpes simplex virus for replication.  This virus is a single stranded DNA virus 
that is able to infect nondividing human cells and stably integrate into a specific locus on 
chromosome 19 (153).  Structurally, these viruses are the smallest among gene therapy vectors at 
25 nm in diameter.  Like adenoviruses, the AAV genome contains inverted terminal repeats 
which upon uncoating within the host nucleus fold to form palindromic structures that serve as 
primers for DNA synthesis.  The viral encoded machinery is derived from overlapping sequences 
that take advantage of alternative splicing to generate multiple genes from the same transcript 
(177).  Two of these genes, Rep78 and Rep68, comprise the regulatory elements that are 
necessary for DNA replication and gene expression regulation (183).   
Therapeutic versions of AAV are gutted vectors that contain only ITR sequences with the 
transgene in place of the capsid genes (154, 155).  Propagation of AAV vectors is commonly 
carried out in 293 cells.  These cells are co transfected with a gutless infectious rAAV vector and 
a plasmid that provides the missing rep and cap genes followed by infection with an E1A deleted 
adenovirus.  Alternatively, stable cell lines can be generated that express the rep and cap genes or 
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HSV-1 and/or Adenoviruses can be engineered to provide these functions in trans.  Recently, a 
cell line has been generated by lentiviral transduction that provides rep, cap, E2, and E4 (125).  
Development of cell lines for production of AAV has been hindered by the toxicity of the 
essential rep gene and elaborate schemes have been devised to complement this gene through 
inducible systems (118, 130, 137, 199).  For clinical applications, however, the helper virus must 
be removed from stocks to avoid toxicity associated with the helper virus and concentrate the 
rAAV.   
Purification of rAAV is traditionally carried out through density gradient centrifugation 
which is not amenable to large scale production. However, recent developments in the field of 
viral purification using ion exchange chromatography have yielded improvements in AAV 
production (36, 138, 168).  Size exclusion chromatography has also been successfully 
implemented due to the small size of the virus (168).  Even with these advances in AAV 
purification the scalability remains an issue.   Another limitation to AAV based gene therapy is 
the need to co- transfect the helper functions which severely limits the economy of scale for this 
vector.  Complicating development of AAV as a gene therapy vector is the lack of correlation 
between in vitro and in vivo functional gene transduction (66, 103).  Furthermore, random 
integration in the absence of helper functions in vivo needs to be investigated in greater detail 
before this vector strategy is implemented as this can lead to insertional mutagenesis.  The risk 
associated with AAV based gene therapy is exemplified by the recent death in a arthritis trial 
where a fatalilty halted the study (87).     
1.1.2.4 Pox Virus 
Poxviruses are among the most complex viruses studied to date.  The double stranded 
DNA genome is on the order of 190 kb and they encode approximately 185 open reading frames 
and contains inverted repeats of about 10 kb at each terminus.  The double enveloped virion has 
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an inner core which houses viral DNA dependent RNA and DNA polymerases and is on the 
order of 350 nm in diameter (41).  Once the virus has entered the cell through uknown 
mechanisms, the viral genome remains episomal due to its large size and the virion associated 
proteins direct gene expression in a temporal cascade.  The early genes are synthesized first 
which include DNA processing and metabolism functions.  A subset of these genes have 
sequence similarity to cellular growth factors and when secreted can induce proliferation to 
neighboring cells.  The intermediate phase of gene expression is concomitant with DNA 
replication and downregulation of early gene synthesis.  Poxviruses are unique in that all DNA 
replication occurs inside the cytoplasm independent of the host cell nucleus (41, 162).  A cellular 
protein, Vitf2, which translocates from the nucleus, is essential for transcription of the 
intermediate genes which suggests tissue type specificity (54).  Once DNA replication has 
ensued the structural components of the virus are expressed by the intermediate genes and the 
immature virion becomes enveloped through the trans-Golgi network.  Subsequent transport to 
the cell surface and actin polymerization either directly transports the virus to surrounding cells 
or it is released as an extracellular enveloped virion.  The kinetics of viral replication and egress 
are quite fast compared to other DNA virus with poxviruses producing up to 10000 infectious 
virions per cell in approximately 7 hours (54, 120).  
Poxviruses as gene therapy vectors have been mainly applied to oncolytic approaches to 
tumor models as well as vaccination strategies.  The most widely used poxvirus is vaccinia virus 
since its inception as a successful vaccine for smallpox ((81).  This vector has many advantages 
over other viral systems such as the large genome and subsequently large transgene capacity.  
There is also the possibility of a vector with multiple gene inserts due to the large encoding 
capacity.    One limitation is the need for a safe permissive cell line for large scale generation of 
recombinant viruses.  This cell line must be able to generate progeny poxvirus with the correct 
post translational modifications for correct antigen presentation in the host as well as support 
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high titer growth.   Another drawback of Poxvirus gene therapy is limited lifecycle within the 
host leading to short term transgene expression.   Poxvirus vector transduction may therefore be 
more amenable to transient expression of an antigen for vaccine application.  Herpes Simplex 
Virus 
1.2 HERPES SIMPLEX TYPE 1 VECTORS 
Herpes Simplex Type 1 is an enveloped 152 kb double strand DNA virus that can infect a wide 
variety of tissue types.  This virus is amenable to gene therapy applications for a number of 
reasons.  The large genomic size can house multiple gene or large transgene cassettes with up to 
40 kb inserts.  The virus has two distinct phases of infection that can be taken advantage of for a 
number or different maladies.  In the latent state of infection the genome remains in a dormant 
state within primary neurons and transcribes a short 2 kb transcript referred to as the latency 
associated transcript (LAT).  This LAT promoter can therefore be used to drive expression in the 
neuron for the life of the host.  Such applications include treatment of chronic pain and ion 
channel modulation (10, 25).  The lytic phase of replication can be taken advantage of for 
oncolytic therapy in particular in the brain.  Since the virus remains dormant in post mitotic cells, 
vectors can be made to selectively replicate a wide variety of neoplasia (89, 124, 164, 180).  The 
growth of these vectors is also straightforward since typically they are only missing one or two 
essential immediate early gene products.  However, these vectors can be quite toxic and therefore 
impaired for gene transfer capacity.  The current state of the art of HSV-1 gene therapy is 
described in the following sections highlighting the importance of this vector and the rationale 
for investigations into bioprocessing this type of gene therapy vector. 
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1.2.1 Basic Biology of HSV-1 
The HSV-1 virion is on the order of 200 nm in diameter and is enveloped by a glycoprotein coat.  
The viral envelope contains 11 glycoproteins of which glycoprotein D, glycoprotein B, the 
complex of glycoprotein L/H are essential for entry into the host cell (8, 20, 95).  An amorphous 
collection of proteins referred to as the tegument lies between the nucleocapsid and the 
glycoprotein envelope.  The tegument contains transactivators necessary to initiate productive 
infection as well as alter the cell state for selective replication of the HSV-1 genome.  Upon 
attachment and entry, the virus sheds the glycoprotein envelope and is transported to the nucleus 
through association with microtubules (45, 91).  Tegument proteins are also liberated upon 
capsid release.  These proteins serve to alter host function during viral replication.  Once the 
nucleocapsid reaches the nucleus, the genomic content is released and transcription occurs 
through host RNA polymerase II.  HSV-1 gene expression is coordinately regulated in an 
ordered temporal cascade (53).  Three kinetic classes of gene expression illustrate the pattern of 
HSV-1 protein production.  Immediate early (IE), early (E), and late (L) are the temporal 
categories assigned to each class. IE genes are characterized by expression in the absence of host 
or de novo protein expression.  These gene products’ functions comprise transcriptional 
regulation, mRNA processing, and host immune evasion.  Dynamics of IE gene expression are 
regulated at the promoter level through viral and host protein DNA interactions.  Tegument 
protein VP16 directs the assembly of viral and host proteins at the site of IE promoters.  Host 
cellular factor (HCF), a proteolytically cleaved protein, associates with VP16 and accumulates 
host transcription factors to cis acting TAATGARAT (R represents any purine) sequences on IE 
promoters (83, 195, 196).  Early genes represent the replication machinery encoded by the virus 
which includes DNA polymerase and ribonucleotide reductase.  Late genes denote the structural 
components of the virion such as capsid and glycoproteins as well as tegument proteins packaged 
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in the virion.  In the absence of IE gene expression, the virus cannot initiate a productive 
infection and the cascade is stalled.   The next three sections highlight the roles of three critical 
immediate early gene products. 
1.2.1.1 ICP4 
Of all immediate early genes, ICP (infected cell protein) 4 has been implicated as a 
requirement for productive infection (6, 11, 37, 39).  This gene is present in two copies within 
the genome on each side of the unique short region adjacent to an origin of replication (121).   
ICP4 contains different functional domains which permit direct DNA binding, transactivation, 
dimerization, and nuclear localization (40).  ICP4 has been shown to interact directly with basal 
transcription factors such as TATA binding proteins (TBP), Transcription Factor IID (TFIID), 
and TFIIA.  The indirect binding of ICP4 to early (thymidine kinase) and late (glycoprotein C) 
promoters infers its ability to transactivate essential downstream genes (98, 165).  Additionally, 
this protein is immunogenic in mouse models and imparts cytotoxicity through sequestration of 
transcription factors by inhibiting host transcription (62, 108).  
1.2.1.2 ICP0 
ICP0 has been shown to transactivate both cellular and viral promoters in a non-specific 
fashion (50, 136).  This viral protein is also a mediator of cytotoxicity most likely due to the E3 
ubiquitin ligase activity that has been implicated in setting the cell cycle and altering the host 
response to infection (65, 113).  The open reading frame of ICP0 contains multiple domains 
necessary for biological activity.  The  amino terminus contains a zinc binding RING finger 
motif with a ubiquitin specific protease, nuclear localization signal, and a self multimerization 
site at the carboxy terminus (48).  These functional domains have been removed to create various 
insertional mutants whose phenotype has allowed clarification of ICP0 activity.  In the absence 
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of the RING finger domain, inhibition of host cellular interferon stimulated genes is ablated 
(100).  Growth phenotypes of ICP0 null mutants are MOI and cell type dependent.  Infections at 
MOIs at or above 1 tend to grow normally in comparison with wild type in Vero cells while 
infections below this threshold display 3 to 4 log differences in productivity (19).  However, in 
osteosarcoma cells, such as U2OS, the ICP0 null mutant grows similar to wild type which 
implicates these cells as having some function that can either rescue the growth phenotype or is 
missing some function that ICP0 specifically targets for selective expression of the viral 
genome(202).   Another feature of this viral protein is the ability to combat host immune 
response to infection.  Several studies have shown that ICP0 can degrade promyelocytic 
leukemia (PML) or nuclear domain (ND10) structures that form at the nuclear membrane in 
punctuate organelles in response to physiological stress such as heat shock or viral infection (47, 
61).  These PML bodies have been shown to repress transcription and gene expression from 
incoming pathogens which has implications on viral spread and productive infection.  The 
toxicity imparted by ICP0 can be attributed to it’s ubiquitin ligase activity.  ICP0 has been shown 
to target specific host response molecules to allow selective replication of the virus  It is 
therefore, critical to disseminate the role of ICP0 and its contribution to the spread of the virus 
for safe clinical mutants that lack this function.  
1.2.1.3 ICP27 
The majority of HSV-1 post-transcriptional processing has been shown to be directed by 
one viral gene, ICP27.  Analogous to the other IE gene products, ICP27 is multifaceted with 
different domains that direct viral functions. This 63 kDa protein has been shown to direct viral 
transcript nuclear transport during infection and is conserved among all herpesviruses.  The N-
terminus contains an RNA binding domain as well as nuclear import and export signals (112, 
156).  Transactivation and early to late gene transition functionalities have been mapped to the 
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C-terminus (169, 170).   Novel studies using fluorescence imaging reveal that this protein has a 
self-interacting domain connecting the N and C termini that is essential for full ICP27 
functionality (207).  These investigations highlight the nature of typical HSV-1 IE genes in that 
they are multifunctional to efficiently associate with host cell machinery to regulate the genetic 
cascade of expression.   
Timely expression of ICP27 is necessary, in conjunction with ICP4, for propagation of 
HSV-1 in culture.  The transcriptional transition from the early to late gene class requires the 
presence of ICP27 in that it can downregulate early transcripts and promote late gene 
transcription (80, 144, 191).   Furthermore, detailed work on prereplicative ND10 bodies reveal 
that ICP27 colocalizes with ICP0 and ICP4 in these nuclear structures upon infection indicating 
that this protein may serve a regulatory role in the viral life cycle (123).  Along these lines of 
evidence, ICP27 interaction with splicing regulatory factors and global inhibition of transcript 
splicing has been implicated by numerous studies (18, 23, 109, 159).   Likewise, ICP27 has been 
shown to shuttle between the nucleus and cytoplasm during infection.  This transport of ICP27 is 
associated with cellular factors linked to RNA binding and RNA export from the nucleus 
indicating that HSV-1 can efficiently exploit the natural RNA transport pathways to aid in gene 
expression.    Relocalization and host shut off function of ICP27 most likely serves to alter the 
host cell in such a way as to selectively allow viral transcription and repress cellular functions 
that could inhibit the progression of infection.   
1.2.2 Construction of HSV-1 Vectors 
HSV-1 vectors can be utilized in three different ways depending on the application and method 
of construction.  Outlined below are the current methodologies for construction of HSV-1 based 
gene therapy vectors. 
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 1.2.2.1 Amplicon Vectors 
The safest way to deliver genetic material is by eliminating pathogenic effects of the 
virus while maintaining stable expression of the transgene.  Amplicon vectors are essentially the 
viral DNA backbone in a plasmid form with an origin of replication, a packaging sequences, and 
cis acting elements to drive expression of the exogenous gene.  Since this DNA structure is 
minimal, the payload capacity is up to 100 kb which makes this strategy quite attractive.  
Likewise, since there are no viral genes associated with amplicons, the toxicity profile is superior 
due to the lack of reactivation, complementation, or recombination with latent genomes.  To 
propogate these vectors helper virus must be supplied to provide in trans gene functions that 
amplify and package the amplicon DNA into virions.  This helper virus, however, can 
contaminate viral stocks leading to poor toxicity profiles and difficulties in scale up (84).  
Currently, bacterial articificial chromosomes (BAC) are used to provide the missing HSV-1 gene 
functions.  These BACs lack a packaging signal and one essential gene, usually ICP27.  This 
approach leads to fewer contaminating helper virus particles since (i) the BAC genome cannot be 
packaged into virions and (ii) the virus is defective without the essential gene, and (iii) the helper 
genome containing the BAC is considerably larger so packaging is not as efficient.  Co-
transfection of complementing cell lines with BAC helper virus and amplicons can yield up to 
107 transducing units/ml, but large scale production is limited due to the need for expensive 
transfection reagents. 
1.2.2.2 Conditional Replication Vectors 
HSV-1 vectors that replicate in certain cellular microenvironments are normally devoid 
of viral replication machinery.  The selective replication of HSV-1 vectors has direct application 
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in oncolytic therapy.  These viruses are replication defective in normal post mitotic tissue such as 
primary neurons.  However, in actively dividing neoplasms these viruses are supplied the 
missing functions in trans which include viral gene necessary for DNA metabolism such as 
thymidine kinase, ribonucleotide reductase, and the viral DNA polymerase.  Mutations in these 
genes along with the neurovirulence factor (ICP34.5) which is diploid in the viral genome, allow 
selective replication in the microenvironment of a brain tumor in contrast to normal non-dividing 
glial cells.  HSV-1 mutants lacking neurovirulance factor ICP34.5 have been shown to efficiently 
infect and reduce tumor mass in both mouse, primate, and human models (110, 117).  This 
vector, G207, has been deleted for ICP6, the viral ribonuceotide reductase, and both copies of 
ICP34.5 allowing it to only replication once in the glioma.  Through homologous recombination 
of wild type virus, KOS, with a cotransfected targeting plasmid that encodes the LacZ gene 
flanked by upstream regulatory sequences of ICP6 and a stop codon introduced into the 
downstream elements after the LacZ insertion (58).  This strategy allows for marker transfer and 
relatively simple selection of blue plaques in the presence of beta galactosidase staining.  
Removal of ICP34.5 was confirmed by restriction digest and southern blot analysis (28).  The 
added advantage of using HSV-1 for this mode of therapy is that latency associated genomes is 
apathogenic to the surrounding healthy glial cells.  Oncolytic therapy is an attractive approach as 
it allows selective replication specific to the disease state.  This method of viral construction and 
application is now being extended to other DNA viruses such as adenoviruses and vesicular 
stomatitis viruses (189, 197).   
1.2.2.3 Replication Defective Vectors 
Replication defective vectors represent a broad area of research for the delivery of 
exogenous DNA (160, 205).  These vectors are typically mutated by one or more essential 
functions that will preclude viral DNA replication and thus render the virus replication defective.  
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Normal construction of these viruses is carried out in a similar fashion to selective replication 
vectors.  Marker transfer remains a convenient method to removing a particular locus and 
replacing the viral gene with a colorimetric marker such as EGFP, lacZ, or RFP flanked by the 
homologous sequences in a targeting plasmid via co-transfection and infection with the parent 
virus (92, 93).   
These viruses are normally propagated to high titer through the use of a complementing 
cell line that provides the missing gene products in trans.  The complementing producer cell 
lines are constructed to express the viral genes only under the context of infection.  Varied 
complementation/mutation strategies have been employed to generate and propagate replication 
defective HSV-1 mutants depending on the tissue type and kinetics of expression.  Of the 
immediate early genes, ICP4 and ICP0 are the most toxic in cell culture.  In conjunction with 
deletion of the ICP27 locus, removal of ICP4 and ICP0 dramatically removes the toxicity of the 
vector while allowing multiple or relatively large transgene insertions into the vector backbone.  
This strategy has led to the generation of triple and quadruple mutant vectors devoid of any 
immediate early function (150).  Another approach is to preclude the expression of the 
immediate early class of genes by constructing VP16 mutants.  Since the tegument protein, 
VP16, can efficiently transactivate the immediate early class of genes, its absence should 
theoretically prohibit immediate early synthesis and subsequently viral DNA replication.  
Multiple deleted viruses that lack the VP16 and UL9 (origin binding protein) loci are completely 
incapable of replication within Vero cells up to an MOI of 30 (203).  However, the issue of leaky 
viral promoters in different tissue types remains an issue.  Therefore, the safest vectors for gene 
transfer will have the most cytotoxic IE genes ablated to remove the opportunity for viral 
replication. 
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 1.2.3 Applications of HSV-1 Vectors  
The direct application of HSV-1 for gene therapy has proven successful in a wide variety of 
tissue types owing to its natural ability to infect many tissue types.   Gene transfer is possible in 
primary epithelia, peripheral nerves, adipose tissue, hepatic tissue, cancerous tissue, and skeletal 
muscle (1, 33, 55, 59, 135).  This array of potential tissue types for therapy highlights the 
capacity of this vector type for gene transfer applications.      
HSV-1 as a gene transfer vehicle has been exploited for numerous applications of human 
disease.  The use of HSV-1 as an oncolytic therapy has proven successful in both the primate 
model and in humans (106).  The use of vectors attenuated for the virulence factor, ICP34.5, and 
the viral encoded DNA polymerase UL39 have shown improved safety and sensitivity to prodrug 
administration such as ganciclovir.  This strategy allows an extra level of protection since 
delivery of ganciclovir will inhibit virus replication and reduce possibility of herpes encephalitis 
once the virus has been delivered.  These vectors also show no effects on motor or cognitive 
development as assayed by open field maze test task (139).   
Neuropathies associated with pain also represent an active area of research in the field of HSV-1 
gene therapy.  Recent efforts have proven useful in ectopically expressing the transient receptor 
cation potential vanilloid (TRPV1) receptor and subsequently searching for receptor modulators 
using a selective viral replication strategy (172).  These studies have led to enhanced 
understanding in pain signaling and receptor physiology.  Recent efforts have revealed reduced 
pain response by the hind footpad lifting tests in response to heat in a mouse model.  The use of 
HSV-1 as a tool is also employed in the study of early embryogenesis for identifying critical 
components in development.  A selective replication system has been recently developed with 
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replication driven by a developmental promoter controlling ICP4.  This system allows the 
identification of cellular factors that can drive the expression of the essential immediate early 
gene ICP4 that will drive viral replication.  cDNA libraries can be routinely constructed and 
pools clonal isolates of HSV-1 vectors housing these libraries are now being developed.  Since 
HSV-1 can infect and transduce a wide variety of tissue types, a library screen based on certain 
disease states has the potential to uncover previously unknown mechanisms in disease models.   
The use of HSV-1 as a tool for investigating molecular biology dynamics as well as virus host 
cell interactions represents a promising arena of molecular therapy based on HSV-1.  
Furthermore, insight gained from cDNA library screens based on HSV-1 vectors will serve to 
direct gene therapy in a high throughput manner. 
1.3 MANUFACTURING OF HSV-1 VECTORS 
HSV-1 vectors are routinely produced from cell culture and subsequently purified by 
centrifugation.  There are many limitations in both the upstream and downstream components of 
manufacture which represents a major bottleneck to bringing these vectors to clinic.  The main 
areas under current investigation are scale up and downstream purification of HSV-1 vectors and 
transfer of this technology from the bench to cGMP environments. 
1.3.1  Production of HSV-1 Vectors from Cell Culture 
HSV-1 vectors are routinely propagated using a mammalian host cell line.  Vero (African green 
monkey kidney) cells represent the most common cells used for viral vector production owing to 
their lesion in the interferon response and ease of culture (46).  These cells are aneuploid and will 
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grow indefinitely in culture so there are no passage limitations.  Vero based cell culture 
represents similar species origin to humans and therefore has been used to study broad areas of 
disease and molecular virology.    For instance, these cells have been approved by the FDA and 
European governments for biologic production of vaccines against smallpox, rotavirus, and 
poliovirus (85, 140, 192).  Culturing these cells is straightforward, however, viral propagation 
adds another level of complexity.  Critical cell culture considerations are half life of the virus in 
different culture media and relative stability for long term storage.  Studies investigating pH and 
heat sensitivity have outlined important parameters for culture conditions for HSV-1 production 
(134).  Additionally, multiplicity of infection, serum content, and culture confluency at time of 
infection can drastically alter the efficiency of production.  All of these parameters need to be 
optimized to realize scaleable manufacturing methods to transfer technology from bench scale to 
the clinic.     
1.3.1.1 Complementing Cell Lines 
Since most therapeutic viral vectors are missing essential gene functions, complementing 
cell lines need to be generated to provide these functions in trans.  The tissue type used to 
construct these lines is an important parameter for consideration since the FDA imposes strict 
requirements on the acceptable cell lines used for production of biologics.  The most common 
cell types are chinese hamster ovary (CHO), human epithelial cells, PERC6, and Vero cells.  
These cells while, not all continuous, should be free of adventitious agents and non-tumorogenic.  
This last restriction has severely limited production since most tumor lines are able to support 
viral growth to higher titers than normal cell lines.  As well, the limited passage of primary tissue 
makes cell line development difficult.  The more common Vero cells are routinely used since 
they grow continuously while their immortalization has not yet been characterized.   
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The complementing character of the cell line is crucial to propagation of the replication 
defective vector.  Stable complementing cell lines are routinely generated by transfection with a 
plasmid that contains the gene of interest with a drug selectable marker.  The lines then are 
selected by clonal isolation and tested for viral production capacity.  The promoter driving the 
expression of the viral gene is also crucial since uncontrolled expression of the cytotoxic gene 
would normally negate selection.  This promoter must be responsive to infection and be selective 
for the incoming virus.  Since most DNA viruses express their genes in a cascade regulation this 
gene or set of genes are normally of the immediate early class that preclude viral DNA 
replication.  The stability of the complementing cell lines are routinely tested by drug resistance 
as the passage number grows and it has been observed that the complementing activity drops as 
the cell are cultured to higher passages (133). 
1.3.1.2 Cell Culture Configurations 
The type of cell culture configuration can drastically alter the economy of viral vector 
manufacture.  Most common cell culture systems are T-flasks with cells grown in monolayers.  
This configuration however is limited by difficulty in realizing the surface area requirement to 
grow a large scale culture.  Considerable effort is required to culture multiple T-flasks to achieve 
the surface are required to reach manufacturing scale.  Additionally, contamination can easily 
occur as the number of required flasks grows demonstrating this strategy is not efficient for large 
scale cell culture.  An alternative is the use of Nunc cell factories that are monolayers assembled 
in sheets of polystyrene contained in a single unit with one air vent.  While this configuration 
eases the burden of subculturing multiple flasks, inefficient CO2 exchange limits the viability, 
and therefore productivity, of the cells. 
Bioreactor culture remains the choice of most large scale operations due to ease of use 
and limited opportunity for contamination.  For most suspension culture, cell passage is routine 
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while anchorage dependent cell lines require microcarriers to supply substrate for growth.  
Cytodex-1 and Cytodex-3 beads have been shown to support growth of Vero cells in suspension 
as well as production of vaccines and viral vectors (147, 182, 194).   These beads are crosslinked 
dextran with diethylamino ethyl groups that can adhere cells through positive charge interactions 
with the outer cell membrane.  Fibracell disks are an alternative system that relies on the use of 
polyester and polystyrene non-woven fibers that can adhere cells through hydrophobic 
interactions with the outer cellular membrane.  While both microcarrier culture systems support 
growth of anchorage dependent cells in suspension, Fibracell disks rely on the use of perfusion 
culture to deliver nutrients.  The main disadvantage of this system is entrainment that occurs 
when cells adhere to the fibers which has been validated through crystal violet staining.  More 
importantly, virus produced from the cells is also detained within the disks.  For large scale 
manufacture of HSV-1 based viral vectors Cytodex beads remain the state of the art for culture 
configuration.  In this system air is either sparged in through a downcomer or through the 
headspace.  The bubbles that arise from sparged air can lead to reduced cell viability due to 
bursting within the cell monolayer on the microcarriers.  Distributor design has led to decreased 
bubble size that overcome this limitation, however, accurate monitoring of dissolved oxygen 
within large scale systems remains a limitation to development of this cell culture configuration 
due to low specific oxygen uptake rates of the cells, sensitivity of the cells to dissolved oxygen, 
and the kinetics of the response to controlled dissolved oxygen (57, 132, 148).  With advances in 
the areas of membrane detectors and tighter control these issues will become neglible in the 
future for production cell based biologics. 
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 1.3.2 Purification of HSV-1 Vectors 
HSV-1 vectors have been routinely purified through a variety of methods which include high 
speed centrifugation, sucrose gradient, and column chromatography.  These methods are 
designed to purify the virus from contaminating host cell protein and DNA with advantages for 
each in regards to efficiency, cost, and scalability.  The purification step represents the most 
active area of research since stringent requirements have been set by the FDA for recombinant 
biologics approved for use in humans. 
The harvest step of virus consists of collecting cellular debris and supernatant once the culture 
has reached 80-100% cytopathic effect (CPE).  This morphology is usually characterized by 
cellular membrane blebbing, rounding up of the cells, and detachment from the monolayer.  At 
this point, the cells and supernatant are collected by scraping the remaining cells and salt treating 
the debris with a moderate concentration (0.45 M) of NaCl to compete off any bound virus to the 
cellular receptors or intracellular organelles.  For most HSV-1 viral vectors there will be a 
significant fraction remaining within the cellular pellet.  As the vector becomes more deleted, the 
ratio retained within the cells is increased due to inefficient complementation during 
propagation.  Triple mutants that are devoid of essential functions ICP4, ICP0, and ICP27 are 
particularly attenuated for growth and therefore require extensive processing of the pelleted 
cellular debris while double mutants missing only ICP4 and ICP27 are not as stringent in this 
requirement.  This harvest step includes sequential salt treatment, freeze thawing, and sonication 
to release cellular bound virions. 
Upon harvest, the virions are further purified through step wise filtration through sequentially 
smaller pore size filters.  However, as the filter size approaches the diameter of the virus (0.22 
 24 
um) significant losses can occur so larger (1.2, 0.8 and 0.45 um) filters are routinely used to 
prefilter the virus before either centrifugation or column chromatography.  Since these methods 
are not amenable to large scale purification other techniques have been employed to clarify cell 
debris.   Our lab has developed tangential flow flow filtration as a method to take advantage of 
size separation for separation of virus from cellular contaminants.  DNA contamination remains 
a challenge due to the fact that it can adhere to the viral membrane.  Steps taken to remove 
include detergent and benzonase treatment.  However, these protocols are far from optimized 
since benzonase removal can complicate the harvest by contributing to the contaminating 
nonviral protein content.         
1.3.2.1 Centrifugation 
Pre polishing steps are necessary to remove large cellular debris that remains upon 
filtration.  Traditionally, this is carried through gradient centrifugation either through sucrose or 
cesium chloride (126, 127).  While these purification steps yield relatively high purity genome 
containing virions, their adaptation to large scale is limited.  Therefore, centrifugation remains a 
common intermediate step in viral vector purification.  High speed centrifugation can achieve 
concentrated stocks however aggregation and cosedimented protein complicate this process.      
1.3.2.2 Ion Exchange Chromatography 
Vigorous purification methods that can separate genome containing vectors which are 
adaptable to large scale remain critical to advancing gene therapy vectors into clinic.  Strict FDA 
requirements for vector purity and concentration have resulted in numerous investigations into 
optimal separation technologies.  These include immunoaffinity, membrane adsorption, ion 
exchange, and molecular imprinting.   Ion exchange chromatography represents a scalable robust 
method for purifying proteins as well as viral vectors.  This strategy relies on electrostatic 
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charge-charge interactions to separate molecules of interest.  Salt, usually in the form of NaCl, is 
loaded onto the column and the appropriate ion binds to the resin.  By exchanging either a cation 
such as sodium or an anion such as the chloride ion, the virus can adsorb to the column matrix.  
These matrices usually consist of crosslinked agarose with functional moieties covalently linked 
to impart charge specificity.  The crosslinked matrix has an added advantage of acting as a 
molecular sieve separating small molecular mass proteins while allowing the virus to pass 
through or bind to the functional groups.  These functional groups are normally represented as a 
strong or weak ion exchanger.  Strong cation exchangers consist of negatively charged 
sulfopropyl (SP) functional groups while strong anion exchangers are usually a positively 
charged quarternary amine (Q).    Loading conditions such as pH, salt composition, and flow rate 
dictate the capture efficiency of the target molecule.  In the case of virus purification, in 
particular enveloped virions such as HSV-1, the glycoprotein layer can be targeted to the matrix 
by altering the electrostatic interactions through ionic strength and proton concentration of the 
load material.  The salt concentration will also alter the viscosity of the loading material which 
can affect the hydrodynamic properties of the virus as it binds to the column.  Furthermore, mass 
transfer effects must be considered as the flow rate will affect contact time as well as the shear 
rate the virus experiences as it traverses the interstitial space of the packed column.  All of these 
parameters are critical to optimizing the purification process and the biophysical properties of the 
virus must be considered to achieve optimal purity while maintaining scalability. 
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2.0  MATERIALS AND METHODS 
2.1 VIRUSES AND CELLS 
All viruses are based on the KOS strain of HSV-1.  Nurel P is a double IE mutant missing ICP27 
and both copies of ICP4 originating from the d120 vector (38, 111).  The promoter of ICP22 has 
been deleted of the VP16 responsive TAATGARAT motifs rendering its expression profile 
under the beta regime of HSV-1 temporal cascade (151).  This mutation also removes the 
immediate early toxicity associated with ICP22 in that it can stabilize the transcript processing of 
the toxic IE ICP0 gene (22).  Additionally, the TNF-α gene driven by the HCMV promoter 
resides in the UL41 (virion host shutoff gene) locus along with the rat connexin 43 cDNA driven 
by the ICP0 promoter and the enkephalin gene in the ICP4 locus (128).  This vector is 
propagated on 7B cells which are Vero cells that  contain the ICP4 and ICP27 genes on a single 
transcript driven by their own natural promoters (105).  The JDTOZHE vector (provided by 
David Krisky) is a progeny of TOZHE (93) which is devoid of the IE genes ICP22, ICP27, and 
both copies of ICP4.  The UL41 locus has been replaced by the LacZ coding sequence driven by 
the ICP0 promoter.  One genomic copy of the joint region spanning UL54 to US2 of the KOS 
backbone comprising 15 kb is also missing in JDTOZHE constraining the genomic configuration 
in a single isoform as opposed to the four equimolar inversion isoforms during normal infection.  
The EGFP transgene is driven by the HCMV promoter and with the SV40 polyA in both of the 
ICP4 loci.  JDTOZHE can be propagated on ICP4 and ICP27 complementing cell lines with 
different efficiencies relative to the complementation profile of ICP4.  Our laboratory uses three 
 27 
different ICP4 and ICP27 complementing cell lines (7b, 433, and Q5) to propagate triple mutants 
depending on the backbone.  433 cells are a progeny of N23 cells transfected with the 4BLA 
plasmid. QOZ22REH1 (provided by David Krisky) is a quadruple mutant vector missing all IE 
gene functions with the HCMV promoter controlled expression of EGFP in the ICP0 locus 
flanked by the SV40 polyA.  The UL41 locus contains the LacZ transgene cassette driven by the 
ICP0 promoter.  In addition, the ICP22 promoter controls expression of the dsRED2 gene at the 
ICP22 locus replacing this gene.  JDQOZEH1 (provided by David Krisky) is another quadruple 
mutant that is a progeny of JDTOZHE that is missing both copies of ICP0 and the HCMV driven 
EGFP cassette in the ICP0 locus.  Both QOZ22REH1 and JDQOZEH1 require ICP4 and ICP27 
to replicate in cell culture.  In addition, ICP0 is also required since the vector backbone is 
severely deficient for essential IE gene functions.  The Q backbone of the KOS virus is routinely 
propagated in our laboratory with 01 cells that are progeny of N23 cells that house the ICP4 gene 
driven by the ICP0 promoter and the ICP0 gene driven by the ICP4 promoter.  All cell lines are 
propagated in Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies, Inc. 
Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS Atlanta Biologics, Atlanta, 
GA), 100 U/ml penicillin/streptomycin, and 2mM glutamine (Invitrogen Corporation, Carlsbad, 
CA) at 37°C in 5% CO2 humidified air.  Q5 cell lines were created by transfecting N23 cells with 
a plasmid containing the ICP0 promoter driving ICP4 and ring isolated after passage in 50 ug/ml 
Blasticidin S HCL (Sigma-Aldrich, St. Louis, MO).  01 cells were constructed by transfecting 
Q5 cells with a plasmid bearing the ICP0 gene driven by the ICP4 promoter and ring isolated 
with 20 ug/ml of Hygromycin (Sigma-Aldrich, St. Louis, MO). 
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2.2 CONSTRUCTION OF IE GENE EXPRESSION PLASMIDS 
The plasmid (4BLA provided by David Krisky) bearing the ICP4 coding sequence driven by the 
ICP4 promoter (SphI (131733)to DdeI (126765) of KOS) used to construct the ICP4/ICP27 
complementing cell line (433) was used to subclone a plasmid devoid of the ICP4 promoter by a 
Sal I digestion which gave a 500 bp  and a 4.5 kb fragment.  This 4.5 kb fragment was gel 
isolated via the Geneclean kit (QBIOgene, Morgan Irvine, CA), blunted via Klenow enzyme 
(New England  Biolabs, Ipswitch, MA), HindII linker ligation, and transformed into GC5 
(GeneChoice, Inc. Gaithersburg, MD) competent E.Coli to create plasmid 4BLA-H.  Plasmid 
pUC19 (New England Biolabs, Ipswitch, MA) was digested with PstI and treated with T4 DNA 
polymerase to remove 3’ overhangs to create pUC19-P.  The full ICP0 promoter was subcloned 
by NcoI digestion of the full ICP0 plasmid 28.4 (provided by Ying Jiang), blunted via Klenow, 
and gel isolated resulting in a 1.7 kb fragment containing the full ICP0 promoter.   The 1.7 kb 
fragment was ligated into the blunted PstI site of plasmid pUC19-P to create plasmid pUC19-O.  
Plasmid pUC19-O was digested with XbaI, blunted via Klenow, and HindIII linker ligation to 
create pUC19-O-H.  Plasmid pUC19-O-H was digested with HindIII and gel extracted to isolate 
the ICP0 promoter flanked by HindIII sites as a 1.7 kb fragment.  This 1.7 kb fragment was then 
ligated into HindIII digested 4BLA-4 via the rapid ligation kit (Roche Diagnostics, Mannheim, 
Germany) to create plasmid S0-7 which has the ICP0 promoter driving ICP4 with the 
mammalian selectable marker blasticidin.  This plasmid was then amplified in GC5 competent 
cells under ampicillin 10 ug/ml (Sigma Aldrich St. Louis, MO) selection. 
 29 
Plasmid HXSc5 (provided by David Krisky) is a sublcone of pREP4 (Invitrogen, 
Carlsbad, CA) with the following modifications: the SacII-BamHI fragment of the ICP4 
promoter from plasmid 4BLA driving the ICP0 coding sequence from the ATG to the HpaI site 
and a EcoRV to ClaI deletion to remove the EBNA-1 gene.  The HpaI site was blunted and 
changed to BglII via linker ligation.  The ICP4 promoter construct driving ICP0 resides as a 
PmeI to XbaI 3 kb fragment. 
2.3 QUANTITATIVE REAL TIME PCR 
RNA was harvested from infected monolayers by first washing the cells twice in fresh 
PBS and subsequently scraping the cells into a lysis buffer provided in the Qiagen RNEasy kit.  
Cells were homogenized using Qiashredder columns and subject to RNA purification according 
to the manufacturers instructions.  cDNA was generated by first annealing random hexamer 
primers (Roche) to RNA eluted from the Qiagen columns.  Reverse transcription was then 
carried out in the presence of 10mM dNTPs and 1 Unit of SuperScript III reverse transcriptase 
(Invitrogen) at 50°C for 50 minutes.  Reverse transcription reactions were heat inactivated at 
75°C for 15 minutes and kept at -20°C for long term storage. Quantitative PCR reactions were 
performed through the use of an ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems).  The double differential method is used to calculate the amount relative to both an 
endogenous gene (18s) and a calibrator (plasmid containing the coding sequence) where ΔΔCT is 
(CT sample – CT 18s) – (CT background – CTcalibrator).  CTbackground is obtained from an RNA sample 
without reverse transcription.  The calibrator plasmid also serves as a control from assay to 
assay.  Primer and probe sequences for HSV-1 and cellular genes are as follows: ICP4 Forward 
Primer: GGTGGCTCCAGAACCCG, ICP4 Reverse Primer: AAGGAGCTGCTGTTGCGC, 
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ICP4 Probe: CAGGCCTGCTTCCGGATCTCGG, ICPO Forward Primer: 
AACGCCAAGCTGGTGTACCT,   ICP0 Reverse Primer: TCACGATCGGGATGGTGC, ICP0 
Probe: TGACGCCCAGCGGGTCGTTC, ICP27 Forward Primer: 
TTGATATGCTAATTGACCTCGGC, ICP27 Reverse Primer: ATTCCAGGTCGTCGCGG, 
ICP27 Probe: TGGACCTCTCCGACAGCGATCTGG, TK Forward Primer: UL1 Forward 
Primer: GGGTTTTTTGGAGGACTTGAGTT, UL1 Reverse Primer: 
CAAGCGCGTTTCTGTTTCC, UL1 Probe: CCCCGCGTTTCCTGCCAACA, gD Forward 
Primer: CCCCGCTGGAACTACTATGACA, gD Reverse Primer: 
GCATCAGGAACCCCAGGTT, gD Probe: CTTCAGCGCCGTCAGCGAGGA, 18s Forward 
Primer: CCCGAAGCGTTTACTTTGAAA, 18s Reverse Primer: 
CCTCAGTTCCGAAAACCAACA, 18s Probe: CGCCTGGATACCGCAGCTAGGAATAAT.    
  
2.4  PROTEIN EXPRESSION ASSAY 
Infected monolayers were rinsed twice with fresh 1X PBS and overlayed with RIPA 
Lysis Buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1.0% Triton X-100, 1.0% 
Deoxycholate, 5 mM EDTA, 1X Protease Inhibitors (Sigma Aldrich, St. Louis, MO) at 5.5 
uL/cm2.  Collected cell lysate was incubated at 5°C for 15 minutes vortexing every 5 minutes.  
Cell lysate was collected by centrifuging at 10,000 rpm for 10 minutes and collecting the 
supernatant.  Protein concentrations were determined by BioRad BSA kit and the lysates stored 
in aliquots at -20°C if not used immediately.  Equal amounts of protein were boiled for 15 min in 
NuPAGE LDS Sample Buffer (106mM Tris HCL, 141 mM Tris Base, 2% LDS, 10% Glycerol, 
0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.175 mM Phenol Red) and subjected to 
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resolution by NuPage precast Bis Tris polyacrylimide (4-12%) gels at 100 V run in MOPS SDS 
Running Buffer (50mM MOPS, 50 mM Tris Base, 0.1% SDS, 1mM EDTA).  Resolved proteins 
were transferred to a PVDF membrane using the XCell Blot Module at 22 V for 1.5 hours in 
NuPAGE Transfer Buffer (25 mM Bicine, 25mM Bis Tris (free base), 1mM EDTA).  
Membranes were blocked in 1X PBS containing 6% FBS and incubated overnight with primary 
antibody concentrations (1/1000 ICP27, ICP4, and ICP0 (Fitzgerald, Concord, MA), 1/1000 VP5 
(Virusys Corporation, Sykesville, MD), 1/1000 ICP22 (kind gift from P. Schaffer), gB (gift from 
W. Goins)) at 5°C.  Membranes were washed three times for 15 minutes each in 1X PBS and 
incubated with secondary antibodies (anti-mouse HRP (ICP4), anti-rabbit HRP (ICP0), anti-
mouse alkaline phosphatase (VP5) at 1/1000 concentration or anti-rabbit alkaline phosphatase 
(ICP22 and gB) in 6% FBS in 1X PBS (ICP4 and ICP0) or 1X TBS (VP5, ICP27, ICP22, and 
gB).  Bands were developed by either NBT/BCIP (VP5, ICP27, ICP22, or gB) or horseradish 
peroxidase (ICP4 and ICP0).  Goat anti-SAG (Everest Biotech, Oxfordshire, UK) was used at a 
primary concentration of 1/100 and developed via anti-goat HRP at 1/750.  A prestained 
molecular  marker (Biorad Laboratories, Hercules, CA) was used to match molecular weights. 
 
2.5 VIRAL GROWTH AND CELL GROWTH ANALYSIS 
Complementing cell lines were assayed for growth by trypan blue exclusion dye at selected times 
post seeding in tissue culture flasks or well plates.  Viral propagation was carried out by seeing 
cells at subconfluency in either tissue culture flasks or well plates in accordance with the 
experiment.  For large scale propagation T-150 flasks were seeded with 13E6 cells and infected 
at an MOI of 1 to 0.01 one day post seeding.  For each T-150, 2 ml of virus was incubated at 
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37°C and agitated by rotating the flask every 15 minutes to distribute the virus along the 
monolayer.  10 ml of growth medium was then added to the flask and at 24 HPI the flask was 
moved to 33°C.   JDTOZHE was propagated on Q5 (0d4) cells, Nurel P was grown on 433 (4d4) 
cells, JDQOZEH1 and QOZ22REH1 were grown on 01 and 0440 cells respectively.  JDTOZHE, 
JDQOZEH1, and QOZ22REH1 were grown at an initial MOI of 1 and media was supplemented 
at 400 nM Trichostatin A (91).  Nurel P was grown on complementing cells at an initial MOI of 
0.01.  As CPE approached 100% cells and virus were harvested and treated with 0.45 M (final 
concentration) NaCl to release cellular associated virus.  Salt treatment was carried out by 
rotating cells on a LabQuake rotary shaker (Becton Dickinson, San Diego, CA) for 45 minutes at 
room temperature.  Once in 0.45 M NaCl the virus can be stored for up to a month at 5°C before 
further purification.  As needed the virus stock can either undergo high speed centrifugation or 
ion exchange chromatography.  Prior to either treatment, the virus stock is clarified by passing 
through a 0.8 micron bottle top filter (VWR, West Chester, PA) under house vacuum.  High 
speed centrifugation is carried out in a Sorvall S100 Rotor (Thermo Fisher, Scientific, Pittsburgh, 
PA) at 20,000 rpm at 5°C for 30 minutes in Oakridge tubes (Nalgene, Rochester, NY).  Pelleted 
virus is gradually reconstituted by incubation in PBS overnight at 5°C before vortexing to 
resuspend.    
2.6 VIRAL TITRATION 
Titers of viral stocks were carried out on appropriate complementing cell lines by serial dilution 
of virus into culture media and subsequent infection on 0.8E6 cells per well in 35 mm plates.  
Cells were rotated in a rotisserie manner on a LabQuake rotary shaker at 37°C for one hour 
before plating in 6 well plates.  One day post seeding infected cells, media was removed and 
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replaced with DMEM containing 1.25% methyl cellulose to prevent secondary spread of virus 
while moving plates for viewing the progression of infection as evidenced by cytopathic effect 
(CPE).  Titration of virus was quantified by counting plaque forming units (PFU) by removing 
media when CPE was verified by confocal microscopy and staining with Crystal Violet (2 
mg/ml) in a 50:50 mixture of methanol and deionized water.  One day post staining, the wells 
were washed out with water and plaques counted. 
 
2.7 ION EXCHANGE PURIFICATION 
Viruses used in all experiments were purified via ion exchange.  Virus stocks either stored at 5°C 
in 0.45 M NaCl or resuspended pelleted virus were delivered to either a prepacked HiTrap SP  
(cation exchange) or Q (anion exchange) column (GE Lifesciences, Piscataway, NJ) via a P1 
peristaltic pump (GE Lifesciences, Piscataway, NJ) at 0.3 ml/min.  The columns were 
conditioned before virus loading by washing out the manufacturer’s storage material (70% 
ethanol) with 5 column volumes of 0.22 filter-sterilized deionized water.  Columns were 
sterilized by contacting with 0.5 N NaOH for 1 hour at 0.3 ml/min.  Upon sterilization, NaOH 
was washed out with 5 column volumes of 0.22 filter-sterilized 1X PBS pH = 7.0.  5 column 
volumes of 1 M NaCl in 1X PBS pH = 7.0 was then passed through the column at 0.3 ml/min to 
charge the column with the exchange ion (Na+ for SP and Cl- for Q).  Excess NaCl was washed 
out of the columns with 5 column volumes of 1X PBS pH = 7.0.  Upon virus loading the flow 
through was collected and labeled “Load”.  Unbound virus was then washed out with 5 column 
volumes of 1X PBS pH = 7.0 and this fraction was collected and labeled “Flow Through”.  
Bound virus was eluted with 0.22 filter-sterilized 0.45 M NaCl in water.  Fractions were 
 34 
collected manually in 1.5 ml eppendorf tubes at 0.5 ml per fraction.  Upon collection of 13 
column volumes, each fraction was diluted 1/10 in 1X PBS pH = 7.0 and assayed for protein and 
DNA content by UV spectrophotometry (Perkin Elmer, Waltham, MA).  Fractions with the 
highest 260 absorbance were pooled and resuspended in glycerol 10% v/v final concentration 
and stored at -80°C in cryovials (Corning Life Sciences, Lowell, MA). 
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3.0  DEVELOPMENT OF EFFICIENT COMPLEMENTING CELL LINES  
Herpes Simplex Virus Type 1 is a promising vector for gene therapy applications for a variety of 
reasons.  Large scale propagation of this vector is critical for clinic application.  To provide high 
titer virus requires efficient cell line substrates that can stably provide missing gene functions in 
trans with the appropriate timing.  Replication defective HSV-1 vectors require specialized cell 
lines for propagation.  The replication defective genetic backbone is widely varied depending on 
end application and certain gene products must be supplied in adequate level with appropriate 
kinetics.  These cell lines must also adhere to current FDA guidelines if the vectors are to be 
clinical grade.  Ideally, these cell lines also provide the cytotoxic gene products only in the 
context of infection so as to avoid cell death under normal cell growth conditions.  These genes 
should also lack any homology with the input virus to escape recombination events that could 
lead to replication competent virus (RCV).   An efficient complementing cell line is described 
that provides the IE HSV-1 genes ICP4 and ICP27.  The ICP0 promoter was chosen to drive the 
major transactivator ICP4 in an effort to provide higher levels and faster kinetics of expression.  
Quantitative PCR and western blotting reveals a better complementation profile with respect to 
ICP4 under control of the ICP0 promoter in the context of Vero cells infected with JDTOZHE as 
compared to its natural promoter.  Furthermore, the viral yields of the JDTOZHE vector were 
increased by an order of magnitude as assayed by plaque forming units as well as genomic copy 
number.  By optimizing this complementing cell line, we have created a reagent to propagate 
highly defective HSV-1 vectors.  A progeny of this cell line is also described that can be used to 
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propagate HSV-1 mutants that are devoid of all IE functions.  This cell line has the ICP0 gene 
driven by the ICP4 promoter in addition to ICP4 driven by the ICP0 promoter and ICP27 driven 
by its natural promoter.  This cell line provides a further 10-fold improvement in yields with 
respect to triple HSV-1 mutants but remains the only substrate that can be used to propagate 
quadruple mutants without rescue in our lab.    
 
3.1 INTRODUCTION 
Herpes Simplex Virus type 1 (HSV-1) is a 152 kb double stranded DNA virus in which humans 
are the natural host. This virus has been extensively developed for gene therapy applications 
related to diseases of the central and peripheral nervous system. HSV-1 infects a variety of cell 
types with high efficiency such that single vector particles can deliver and express transgenes in 
infected cells.  The principal utility of HSV-1 vectors is the treatment of diseases of the nervous 
system (72, 160).  This is based on the ability to engineer viruses that establish long-term 
persistence in neurons without neuronal damage or the induction of harmful immune responses. 
HSV-1 can persist in the host in a quiescent state referred to as latency and indeed the majority of 
the population are infected with latent virus. Neurons comprising peripheral ganglia are the 
natural sight for HSV-1 latency and virus persistence can be established without replication. Thus 
the removal of virus genes that prevent reactivation from the latent state circumvents spread to 
other individuals and provides an ideal platform for local expression of therapeutic genes in 
absence of viral lytic functions. The vector can be delivered to peripheral sensory neurons by 
simple inoculation of the skin where nerve terminals take up the vector with subsequent transport 
to the nerve cell body in a retrograde manner (56, 99).  Selection of the dermatome for 
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inoculation thus serves a means of vector targeting to specific ganglia without spread to other 
tissues. Transgene expression can be transient lasting for weeks or long-term lasting for many 
months depending on the promoter system used for transgene expression.  Of particular interest is 
the natural viral latency promoter which can express the viral latency transcript for many years 
and can be similarly exploited for transgene expression (9).  Preclinical studies have shown that 
HSV-1 vectors are effective in the treatment of animal models of glioblastoma (64, 71), spinal 
cord injury (101), chronic pain (68), and peripheral neuropathies (24, 114)  For patient 
applications involving the use of highly defective HSV-1 vectors, it is essential to develop 
scalable manufacturing processes that provide high titer, purified vectors without contamination 
by replication competent virus.  
      Natural HSV-1 infection proceeds in a coordinated fashion which is regulated at the 
gene expression level temporally in three distinct classes (12).  The first class of genes, termed 
Immediate Early (IE), comprise the necessary functions for efficient initiation of the infection 
cycle and proper timing and level of expression of the remaining viral functions. The IE gene 
promoters contain one or more copties of  an enhancer sequence that is recognized by a viral 
structural component termed VP16 which together with several cellular transcription factors 
specifically activates expression of the IE genes in the absence of any viral protein synthesis. Two 
of the IE genes, ICP4 and ICP27, are essential for expression of the virus lytic gene program 
while two additional IE genes, ICP0 and ICP22, are not absolutely required for virus growth but 
increase the efficiency of virus replication through the control of cell cycle genes and innate 
immune responses. ICP4 is the major transactivator encoded by the virus which has roles in DNA 
binding as well as repression of IE transcription(7, 8, 15, 23, 27).  ICP27 has been implicated in 
RNA transport and overall inhibition of mRNA splicing (25, 26, 28).  These genes sequentially 
activate the expression of the early (E) class of genes which support viral DNA synthesis and the 
late (L) class of genes that encode the viral structural proteins.  Efforts over the past decade have 
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shown that removal of the immediate early genes ICP4 and ICP27 render the virus completely 
replication defective (16).  Large scale production of this type of vector requires the use of 
complementing cells that provide ICP4 and ICP27 in trans to permit vector replication. The 
further elimination of additional IE genes and other nonessential functions provides vectors that 
are increasingly inert. However, the production of these vectors is more difficult and less efficient 
(21, 22).  Since the ICP4 and ICP0 genes are found in repeat elements surrounding the unique 
components of the virus genome, these genes are diploid in the natural virus. The repeat elements 
allow for recombination to take place which results in isomerization of the unique long and short 
sequences of the virus genome.  This can pose difficulties in modifying genes in the repeat 
elements and thus removal of one copy of each of the repeats  will stabilize the genome into a 
specific form, provide more space for insertion of foreign DNA sequences, and prevent repair 
events.  
     In this study we evaluated the role of complementing gene promoters in supporting vector 
production.  Vero cells engineered to express ICP4 and ICP27 differed greatly in their ability to 
support the growth of a highly compromised vector (JDTOZHE) which was deleted for ICP4, 
ICP27, ICP22 and the internal repeat elements separating the unique long and short components 
of the vector genome. The results indicate that the use of the enriched copy number of the VP16 
recognition motif found in the ICP0 promoter was useful for driving ICP4 expression in 
complementing cells following vector entry. These data support the conclusion that the timing 
and level of ICP4 expression is critical to high titer vector production.  Furthermore, experiments 
with different histone deacetylase inhibitors support the notion that genome de-repression through 
chromatin remodeling can lead to even more enhanced virus yields.  These studies highlight the 
dynamic nature of the host cell response and how these interactions can be exploited to improve 
vector growth. 
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3.2 RESULTS 
3.2.1 HSV-1 IE Complementing Cell Lines  
The choice of cell line is crucial for the translation of vector from bench to clinic.  We compared 
the productivity of different ICP4 and ICP27 complementing cell lines for the double mutant, 
Nurel P, which is missing both copies ICP4 and ICP27.  These cell lines are derived from the 
same parental ICP27 complementing cell line, N23.  A cell line constructed by stable 
transfection with a plasmid that contains the ICP0 promoter driving ICP4 was compared to a cell 
line with the ICP4 promoter driving ICP4 with respect to complementation over a 12 hour time 
course at an MOI of 3.  Cell lysates were collected (See chapter 2 materials and methods for 
details) and assayed by western blot for ICP4.  The ICP0 promoter allowed faster expression 
kinetics of ICP4 over the 12 hour time course during infection with Nurel P (Figure 1).  It is 
important to note that during infection with this viral backbone the ICP0 gene is expressed from 
the virus with efficient kinetics.  This gene allows efficient expression of all viral gene products 
and while not essential provides a cellular environment that is highly permissive for infection. 
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Figure 1. ICP4 Complementation Profile for 0d4 vs 4d4 Cell Lines. 
109 and 433 cell lines were infected with Nurel P at an MOI of 3 and lysed at times 
 indicated (HPI).  The proteins were resolved on 4-12% SDS-PAGE gels, transferred to 
 PVDF membranes and blotted for ICP4.  All samples were normalized to input protein 
 concentration by the BioRad Protein Concentration Assay.  The lower mobility bands in 
 both blots represent nonspecific binding of the primary antibody. 
 
Nurel P growth was compared on both cell lines and revealed similar kinetics and productivity as 
shown in Figure 2.  These results are straightforward since the virus contains both copies of ICP0 
which can dramatically affect the infectious virus yield but also enhance the cytotoxicity (19, 
34).  
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Figure 2. Nurel P Production is equivalent from 433 and 109 Cell Lines.  
 109 and 433 cells were infected with Nurel P at an MOI of 0.1 and harvested at times post 
infection indicated. 
These data indicate that the earlier ICP4 expression was not as beneficial in the presence of ICP0  
delivered by the virus.  To test the strength of the ICP0 promoter a new cell line, Q5, was created 
in a similar manner to the 109 cell line with the full 2 kb ICP0 promoter driving the expression 
of the major transactivator ICP4.  Figure 3 shows the growth properties of another ICP4 and 
ICP27 mutant, E1G6, on the Q5 and 433 cell lines.  E1G6 differs from Nurel P in that the 
transgene in the ICP4 locus contains the EGFP gene driven by HCMV.  There were statistically 
significant differences between the growth phenotypes of E1G6 on the Q5 cell line suggesting 
that the full ICP0 promoter allowed even more efficient expression of ICP4 allowing the viral 
replication cascade to proceed with faster kinetics. 
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Figure 3. E1G6 Production on 433 and Q5 Cell lines.    
433 and Q5 cell lines were infected with E1G5 and harvested at times post infection indicated.  * 
P < 0.005, ** P < 0.01, *** P < 0.05 
To verify that the enhanced expression was indeed a result of faster ICP4 
complementation kinetics a time course was explored for ICP4 expression at 1-6 hours post 
infection with respect to transcript copy number.  Figure 4 suggests that the ICP0 promoter is 
more efficient in providing ICP4 transcript.  ICP27 and ICP0 RNA copy numbers are similar 
between the two cell lines indicating that these immediate early gene products may not be 
responsible for production differences between the two cell lines.  The ICP0 transcript data is 
straightforward since this gene is provided by the input virus and should therefore be similar 
between both infections.  Likewise, for ICP27, the same parental ICP27 cell line was used for 
construction of both cell lines so its kinetics of expression should be similar. 
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Figure 4. IE Gene Transcription from 433 and Q5 in E1G6 MOI = 0.1.   
433 and Q5 monolayers were infected with E1G6 at an MOI of 0.1 and harvested at times post 
infection indicated.  All copy numbers are normalized relative to 18s.  Mock refers to uninfected 
cells under normal cell culture conditions. 
 To validate that the ICP0 promoter is legitimately responsible for the transcript 
differences, a characterization of both cell lines was performed to assess the basal copy number.  
Total genomic DNA harvested by phenol chloroform extraction was subject to quantitative PCR 
similar to the data presented in Figure 4.  Figure 5 indicates that the basal copy number is similar 
between the two cell lines with respect to both HSV-1 IE genes integrated within the cellular 
genome.  From this point the cell line Q5 will be referred to as 0d4 and 433 cells as 4d4 to 
indicate the promoter driving ICP4. 
 
 44 
Basal Copy Number of ICP4 and ICP27
0
5
10
15
20
25
4d4 0d4 
Cell Line
C
op
y 
N
um
be
r P
er
 C
el
l
ICP4
ICP27
 
Figure 5. Basal Copy Number of IE Genes within 0d4 and 4d4 Cell Lines.   
Phenol chloform extracted genomes were analyzed by quantitative PCR for ICP4 and ICP27 
normalized to total cell number.  4d4 represents the ICP4 promoter driving ICP4 cell line and 0d4 
represents the full ICP0 promoter driving ICP4. 
The higher copy number of ICP27 reflects the relative toxicity of the gene as more copies 
are able to be tolerated by the host Vero cells.  The equivalent copy number of the integrated 
ICP4 gene per cell suggests that the promoter activity is indeed responsible for the increased 
transcription and subsequent viral production from the 0d4 cell line. 
3.2.2 Growth of Joint Deleted Triple Virus 
The strength of these cell lines was tested against a poor growing vector JDTOZHE.  Figure 6 
shows the genetic structure of both the wild type KOS and the joint deleted triple mutant 
JDTOZHE. 
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Figure 6. Genetic Backbone of KOS and JDTOZHE. 
 Map of wild type KOS and recombinant HSV-1 constructs.  Schematic of wild type KOS shows 
segmented genome with unique long (UL) and short (US) segments flanked by long and internal 
repeats (LTR and ITR respectively).  Immediate early genes ICP4, ICP27, ICP0, and ICP22 are 
highlighted at their natural loci. 
Figure 6 illustrates the genomic structures of wild-type HSV-1 KOS virus and the highly 
defective derivative JDTOZHE. JDTOZHE has a deletion of the ICP27 gene as well as a large 
deletion spanning the internal repeats between the unique long (UL) and short (US) regions of the 
genome and extending midway through the ICP22 coding sequence in US.  The repeat deletion 
removes one copy each of the ICP0 and ICP4 genes. The second copy of the ICP4 gene, located 
in the remaining US-flanking repeat (TRS), was replaced with the gene for enhanced green 
fluorescent protein (eGFP) controlled by the human cytomegalovirus (HCMV) major IE 
promoter. In addition, an ICP0 promoter-lacZ gene expression cassette is present in place of a 
portion of the UL41 locus.  Thus, JDTOZHE is deleted for all regulatory IE genes with the 
exception of a single copy of the ICP0 gene, and contains two reporter genes (eGFP and lacZ) 
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controlled by different promoters.  This vector requires complementation of the essential ICP4 
and ICP27 genes for growth. 
Complementing cells for JDTOZHE growth were derived from a previously constructed 
Vero cell line that expresses ICP27 from its own promoter following virus infection (105).  This 
cell line was transfected with plasmids containing a selectable gene (Blastidicin S) along with the 
ICP4 coding sequence under control of the ICP4 or ICP0 promoter. Drug-resistant colonies were 
cloned and one of each type, termed 4d4 and 0d4 respectively, were used as the primary lines for 
the studies described here. Using quantitative PCR, we have found that both lines contain 3-5 
copies of the ICP4 gene (Figure 5).  Cell lines were characterized for promoter activity by 
assessing induction of HSV-1 complementing gene transcription in the presence of UV-
inactivated virus.  Upon crosslinking of viral DNA, the virus is unable to replicate and, therefore, 
should provide the transactivating tegument protein VP16 to induce the expression of the 
embedded genes within the cellular chromosome.  Figure 7 shows that the UV-inactivation 
procedure was functional in blocking the expression of ICP4 transcript, determined by randomly 
primed reverse transcription followed by quantitative PCR, from the wildtype KOS on non-
complementing Vero cells at a multiplicity of infection (MOI) of 3 while normal KOS virus was 
able to amplify ICP4 transcript.  Infection with UV-inactivated JDTOZHE on 0d4 and 4d4 cell 
lines display differential activity up to an order of magnitude at 3 and 6 hpi (Figure 7B) 
highlighting the strength of this promoter in the context of VP16 induction.  
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Figure 7. UV-inactivated Virus Induces ICP4 from complementing Cell Lines.  
 A. Vero cells were infected with UV-crosslinked KOS at an MOI of 3 and harvested for RNA at 
times post infection indicated.  ICP4 copy number was obtained from quantitative PCR as 
described in the Methods chapter. 
 
The differential ICP4 induction with the UV-inactivated virus and the basal copy number (Figure 
5) supports the claim that the full ICP0 promoter is substantially more efficient in driving ICP4 
gene expression from the complementing cell line in the context of infection. 
3.2.2.1 Complementing activity of 4d4 cells.   
To determine the complementing efficiency of 4d4 cells for JDTOZHE virus growth, Vero and 
4d4 monolayers were infected with wild-type virus (HSV-1 KOS) and JDTOZHE, respectively, 
at an MOI of 0.01, the standard MOI used in our lab for virus production.  Total virus was 
collected from replicate wells on each of the first 5 days post-infection and titered on Vero or 
4d4 cells.  Virus was added to 1E6 cells in triplicate and seeded into 6 well plates.  Samples were 
collected at times indicated by scraping the monolayer with a cell scraper and incubating at room 
temperature with agitation in 0.45 M NaCl for 25 minutes.  After salt treatment, cell debris was 
spun down at 5,000 rpm for 5 minutes and sonicated for 30 seconds.  Cell debris was pelleted by 
centrifugation again at 5,000 rpm for 5 minutes and the supernatant was frozen at -80°C until 
titration was carried out on 0d4 cells (JDTOZHE on 4d4) or Vero cells (Kos on Vero).   The 
results (Figure 8) showed peak yields of KOS on days 2-5 at or above 1x108 plaque forming 
units (pfu)/ml while the yields of JDTOZHE peaked on day 2 at 1x105 pfu/ml and declined 
rapidly thereafter.  These results showed that complementation of the JDTOZHE growth defect 
by the integrated ICP4 and ICP27 genes of the 4d4 cell line was short-lived and insufficient for 
robust virus growth.  The limited yields of the mutant virus compared to KOS may not be 
surprising as the complementing genes in 4d4 cells, unlike their viral counterparts in the KOS 
genome, are not amplified during virus replication. Hence their expression is not expected to 
increase as a function of viral genome copy number, resulting in a ceiling that may be far lower 
than that reached when the genes replicate with the virus.  This ceiling, in turn, will limit early 
and late gene expression from newly synthesized viral genomes and consequently the formation 
of mature viral particles.  This interpretation supported the suggestion that the expression levels 
of the immediate early complementing genes in 4d4 cells were a key limiting factor in the 
growth complementation of JDTOZHE. 
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Figure 8.  JDTOZHE on 4d4 cells production levels versus KOS on non-complementing Veros 
Viral supernatant and cells were harvested and salt treated at times post infection indiated. 
P values were calculated using the 1 tailed students t test. * = P < 0.01, ** = P < 0.005, *** = P < 
0.001, **** = P < 1E-9. 
3.2.2.2 Expression of complementing viral genes in JDTOZHE-infected 4d4 cells.   
To explore the causes of the weak complementing activity of 4d4 cells, we examined the 
kinetics and levels of ICP4 and ICP27 gene expression induced by JDTOZHE infection.  4d4 cell 
monolayers were infected at an MOI of 3, total RNA harvested at 1, 3, and 6 hpi, and specific 
RNA levels determined by randomly primed reverse transcription followed by quantitative PCR.  
As a positive control, RNA from KOS-infected Vero cells was isolated and processed in the 
same manner.  Typical results normalized to 18S ribosomal RNA amplified from the same 
samples are presented in Figure 9.   
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Figure 9. The ICP0 promoter can deliver ICP4 gene under JDTOZHE infection at MOI = 3 with 
faster kinetics.   
A. ICP4 transcription from JDTOZHE at MOI = 3 at immediate early times post infection. B. 
ICP27 transcription from 0d4 and 4d4 cell lines during JDTOZHE MOI = 3 infection at 
immediate early times post infection.  RNA was harvested and assayed as described in materials 
and methods.  Error bars represent standard error between triplicate samples. 
 
Compared with mock infected cells, ICP4 transcript induction of two orders of magnitude 
indicate that the increase in copy number is due to infecting JDTOZHE.  Figure 9A shows that 
the ICP4 RNA level increased with slower kinetics in the 4d4 cell lines than in the control wild 
type samples, resulting in a greater than 25-fold differential at 6 hpi.  ICP27 RNA levels as 
assayed by quantitative PCR (Figure 9B) are reduced as compared to wild type but the 
differential is a half order of magnitude at a maximum with similar expression kinetics.  While 
the deletion of one copy of the ICP0 gene in JDTOZHE is likely a factor in the lower abundance 
of ICP4 RNA in the 4d4 samples, we do not know whether the reduced levels of ICP4 and ICP27 
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RNA play a role as well.  Overall, since the ICP4 RNA profile showed the greatest disparity 
between the experimental and control samples, these results suggested that insufficient ICP4 
production from the 4d4 genome could be the principal cause of the limited complementing 
efficiency of these cells for JDTOZHE growth. 
To determine whether the RNA measurements based on RT-PCR correlated with protein 
levels, Western blot analyses were performed for ICP4, ICP0, and the major capsid protein VP5 
encoded by the leaky-late UL19 gene.   
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Figure 10. Protein expression kinetics comparing the complementation induction of HSV-1 IE and 
Late gene expression.   
Proteins were collected and resolved on SDS-PAGE gels as described in Materials and Methods.  
A. ICP0 expression at 2-8 hours post infection . 0d4 and 4d4 cells were infected with JDTOZHE 
at MOI = 3.  Vero cells were infected with KOS at MOI = 3.  B. ICP4 expression time course for 
1-12 hours post infection.  C. VP5 expression from 12-20 hours post infection for JDTOZHE on 
0d4 and 4d4 cells.  Kos on Vero cells at MOI = 3 during 2-10 hours post infection. 
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 Figure 10A shows that ICP0 accumulated with comparable kinetics in JDTOZHE-
infected 4d4 cells and KOS-infected Vero cells indicating that this immediate early protein was 
not rate limiting in the production discrepancy between JDTOZHE and KOS.  In contrast, ICP4 
appeared with dramatically delayed kinetics in the mutant-virus-infected cells (Figure 10B). 
Thus, compared to the single-copy ICP0 gene of the mutant virus, expression of the ICP4 genes 
integrated in the 4d4 genome was greatly impaired relative to infection with wild-type virus, 
consistent with the RT-PCR data. VP5 was detected as early as 6 hpi in KOS-infected Vero cells 
with increased abundance at 8 and 10 hpi (Figure 10C), whereas no signal was detected at these 
time points in JDTOZHE-infected 4d4 cells (data not shown). VP5 was first observed in infected 
4d4 cells at 12 hpi with a minimal increase in level at 16 hpi (Figure 10B).  Together, these 
analyses supported the suggestion that ineffective induction of primarily the integrated ICP4 
genes in 4d4 cells precluded robust early and late gene expression from the infecting JDTOZHE 
genome and thereby vigorous viral progeny production.  Given the reduced levels of ICP27 RNA 
and the documented effects of ICP27 on viral transcription, RNA processing and translation 
(157, 158), we do not discount the possibility that ICP27 deficiency also contributes to the 
growth defect of JDTOZHE on 4d4 cells. 
 
3.2.2.3 Complementing activity of 0d4 cells expressing ICP4 from the ICP0 promoter.   
In an attempt to gain better infection-dependent inducibility and expression of the ICP4 
gene in complementing cells, we tested the 0d4 line described earlier. Briefly, these cells were 
derived from the same ICP27-complementing line as 4d4 by transfection of an ICP0 promoter-
ICP4 gene construct and clonal isolation of drug-resistant colonies. We chose the complete ICP0 
promoter to control ICP4 expression because various lines of evidence suggested that this 
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promoter is significantly stronger than the ICP4 promoter (3, 42, 50), yet like the ICP4 promoter 
is essentially silent in uninfected cells. Additionally, the ICP0 promoter is downregulated by 
ICP4 (142), thus preventing run-away overexpression of ICP4 which could result in premature 
cell death or deregulation of the viral gene expression program. Figure 9 shows a comparison of 
ICP4 and ICP27 RNA levels detected in JDTOZHE-infected 0d4 cells (MOI=3) with 4d4 cells. 
The ICP27 (Figure 9B) RNA profiles were similar between the two infected cell lines albeit with 
slight reduction in comparison to wild type control KOS infections on Vero cells. Unlike the 
ICP27 transcription profile, ICP4 RNA levels were higher in 0d4 at all times investigated with 
substantial differentials at 6 hpi (Figure 9A).  Protein expression profiles in JDTOZHE-infected 
0d4 cells were examined by Western blot analyses, as before, and the results are included in 
Figure 10.  Comparison of the 4d4 and 0d4 profiles of ICP0, ICP4 and VP5 shows the 
improvement in expression due to higher transcription rates of ICP4.  While the kinetics of ICP0 
accumulation were similar between the two cell lines, ICP4 was observed 2h earlier in 0d4 cells 
than in 4d4 cells and reached significantly higher levels in 0d4 cells in the first 12 hpi (Figure 
10A).  Consistent with this result, VP5 levels were comparatively increased in 0d4 cells at 12-18 
hpi (Figure 10C); the protein was not detected in either line at or before 10 hpi (data not shown). 
ICP27 protein accumulation was similar between the wild type and JDTOZHE infected 
complementing cell lines (data not shown).  Together, these results showed that 0d4 cells 
provided better complementation of the defects in JDTOZHE gene expression than 4d4 cells and 
strongly suggested that this was due to better inducibility and greater peak activity of the 
promoter driving ICP4 expression in these cells. 
3.2.2.4 Virus yields on 0d4 cells  
To determine whether the increases in complementing viral gene expression observed in 
0d4 compared to 4d4 cells translated into better production of the defective JDTOZHE virus, 
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cells were infected at the standard production MOI of 0.01 and total virus collected daily from 
replicate wells over a 5-day period for titration on 0d4 cells.  Figure 11A shows that the yields on 
0d4 cells were some 5-15 fold higher on different days than the yields on 4d4 cells with three 
fold differences on a per cell basis (Figure 11B). 
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Figure 11. JDTOZHE production is enhanced on ICP4 complementation from the ICP0 promoter 
versus the ICP4 promoter.  
Infections were carried out and harvested as described in Figure 2.  A. JDTOZHE production on a 
per volume basis.  B. JDTOZHE Production on a per cell basis. 
To validate these results, we used quantitative PCR for the UL1 gene to determine the number of 
genome copies in the samples of Figure 11A.  Figure 12 shows that the genome yields were up to 
two orders of magnitude higher on 0d4 cells than on 4d4 cells.  The results of these growth 
experiments are consistent with the interpretation that the earlier kinetics and higher levels of 
ICP4 expression observed in infected 0d4 cells compared to 4d4 cells provide better 
complementation of the JDTOZHE growth defect.  Further examination of Figure 11 shows that 
the PFU titers of the virus preparations from both cell lines fell after day 2 (Figure 11A) whereas 
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the genome yields generally continued to increase, resulting in a decline in PFU:genome ratios 
and thus the biological quality of the preparations after day 2. 
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Figure 12. JDTOZHE genome copy number accumulation is enhanced in cells with ICP4 
complementation driven by the ICP0 promoter as compared to the ICP4 promoter.   
Ul1 was assayed via qPCR from each sample in figure 6 as described in materials and methods. 
 
 
This may be due in part to virus instability at the production temperature (33oC) or high release 
of lactic acid from the cultured cells, but additional causes have not been excluded.  
Burst experiments were used to determine the virus production capacity per cell for the 
two cell lines.  These experiments were performed at an elevated MOI to accomplish direct 
infection of all cells.  By excluding virus production by cells that are secondarily infected 
through lateral spread, this design is better suited to detect direct correlations between gene 
expression and virus synthesis.  Infection at an MOI of 3 revealed that peak yields of JDTOZHE 
on 0d4 cells were higher than on 4d4 cells and were reached earlier (Figure 13A).  
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Figure 13. High MOI production reveals enhanced production levels and similar differences between 
cell lines as with low level infection.  A. Four day time course of MOI = 3 production of JDTOZHE 
on 4d4 vs 0d4 cell lines.  B. Data in part A cast as per cell basis.  **** = P < 1.7 E -6, *** = P < 
0.0005, ** = P < 0.005, * = P < 0.01  
 
 As illustrated in Fig. 13B, the differences in virus yields per cell ranged from 12-fold at 
1 day post infection to just over 4-fold at 4 days post infection.  These results are consistent with 
the earlier production and greater accumulation of ICP4 seen in infected 0d4 cells and thereby 
support the proposed cause-effect relationship between improved ICP4 expression and better 
JDTOZHE growth on 0d4 cells compared to 4d4 cells.  Furthermore, the normalized infection 
production data indicates that these cells are not only responsive to input virus in a dose 
dependent manner but the promoter strength differential is amplified at higher levels of infection. 
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3.2.3 Heterochromatin Reorganization Effect on Viral Production 
The growth phenotype of the triple mutant, JDTOZHE, was investigated in the presence of 
various concentrations of histone deacetylase (HDAC) inhibitors.  These compounds can alter 
the host chromatin state by binding in the active site of histone deacetylases leading to enhanced 
global transcriptional activity through lysine acetylation (96, 171).  Furthermore, use of HDAC 
inhibitors have been used to increase transgene expression from adenovirus and AAV (26, 131, 
178).   HDAC sodium butyrate enhanced viral yield of the highly replication defective vector 
JDTOZHE in a dose dependent manner (Figure 14). 
JDTOZHE Production on 0d4 Cells   MOI = 0.1
0
1
2
3
4
5
6
7
10 1 0.1 0.01
[Na Butyrate] (mM)
PF
U
/C
el
l
Pre
Co Infect
No Drug
 *       P < 0.05        
**     P  < 0.01        ***** P < 0.00005
***   P = 0.005    
**** P < 0.001            
***
****
****
****
**
*
*****
*
 
Figure 14. Sodium Butyrate Enhances JDTOZHE Yields. 
0d4 cells infected with JDTOZHE exposed to Na Butyrate either 1 hour prior to infection or co 
administered with virus.  Infectious virus recovery at 72 HPI was assayed by titration on 0d4 cells. 
 
 58 
JDTOZHE PFU per cell ratios were enhanced up to five fold with either co infection or 1 hour 
pre treatment with sodium butyrate at micromolar concentrations.   Trichostatin A was assessed 
in a similar manner and Figure 15 shows similar improvements at nanomolar concentrations. 
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Figure 15. TSA pretreatment leads to enhanced JDTOZHE production at submicromolar 
concentrations. 
0d4 cells infected with JDTOZHE exposed to Na Butyrate either 1 hour prior to infection or co 
administered with virus.  Infectious virus recovery at 72 HPI was assayed by titration on 0d4 
cells. 
 
Cells were co infected with each HDAC inhibitor or pretreated to investigate whether the cell 
state could be induced to a more permissive environment.  Statistically significant yields were 
obtained at all concentrations of both HDAC inhibitors regardless of the pretreatment or co 
infection regime.  However, TSA pretreatment revealed a subtle improvement in pretreatment at 
much lower concentrations than necessary for sodium butyrate.  The reduction in yield at higher 
concentrations is indicative of drug associated toxicity which is not seen in sodium butyrate.  
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FDA approval of sodium butyrate for use in humans suggests implementation of this production 
scheme will not be limited by safety. 
 
3.2.4   Growth and Expression of Quadruple Mutant Virus 
Viruses that are highly attenuated are attractive for therapy due to a lower toxicity profile.  These 
vectors are the most challenging to propagate due to the nature and complexity of the gene 
expression necessary to complement the multiple missing functions.  A quadruple mutant virus 
which is an offspring of JDTOZHE termed JDQOZEH1 is isogenic but devoid of both ICP0 loci 
replaced with the HCMV promoter driving EGFP cassette.  The genetic map of this virus is 
depicted in Figure 14. 
JDQOZHE
 
Figure 16. Genetic Map of JDQOZEH1 
JDQOZEH1 is an isogenic mutant of JDTOZHE.  The joint deleted quadruple version is devoid 
of ICP0, ICP27, ICP22, and ICP4 with the HCMV-EGFP cassette in the ICP0 locus. 
Construction of an ICP0, ICP27, and ICP4 complementing cell line was carried out to provide an 
efficient substrate for growth for this vector.  Normal ICP27 and ICP4 complementing cell lines 
 60 
are insufficient to grow this vector due the highly crippled backbone.  This difficult growth 
phenotype is hypothesized to be due to lack of sufficient ICP0 expression as this gene can 
markedly affect growth at low input virus (19).  Alternatively, U2OS cells provide a function 
that can substitute for the ICP0 transactivating function (202).  However, since these 
osteosarcoma are not suitable for clinical applications they are not explored for use as a 
complementing cell line for gene therapy use.  Likewise, these cells are very permissive for gene 
expression for a wide variety of viruses therefore selecting a silent gene in this environment 
remains a challenge to cell line construction.  0d4 cells transfected with the ICP4 promoter 
driving ICP0 expression were selected with hygromycin as described in the methods chapter.  
These cells also provide ICP27 under its own promoter and ICP4 under the ICP0 promoter.  
Figure 17 shows the overall productivity from the 4d4, 0d4, and 01 cell lines with respect to 
transgene expression and cell morphology.  
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Figure 17. Enhanced Complementation from 01 Cell Lines 
01, 0d4, and 4d4 cell lines infected with JDTOZHE and JDQOZEH1 at an MOI of 0.1 3 days 
post infection.   
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The presence of ICP0 from the 01 cells allows efficient transduction as evidenced by the overall 
level of EGFP from the JDQOZEH1 vector.  Additionally, this cell line grew the JDTOZHE 
vector more efficiently as shown by the higher percentage of cells with cytopathic effect at three 
days post infection.  The 0d4 line allowed moderate growth of JDQOZEH1 compared to the 4d4 
cells but the lack of ICP0 complementation did not allow sufficient transgene expression as 
suggested by the low levels of EGFP.  Figure 18 shows the productivity differentials for all three 
cell lines.  The 01 cell lines consistently yielded statistically significant yields of this highly 
defective vector suggesting that this cell line can be used to propagate further non-toxic versions 
of HSV-1 vectors.  Furthermore, this cell line has not yielded replication competent vectors as by 
testing on non-complementing Vero cells and PCR for the ICP0 region from 01 cells infected 
with a ICP0 mutant. 
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Figure 18. 01 cells can yield relatively high titer of highly defective HSV-1 backbones. 
4d4, 0d4, and 01 cells were infected with JDQOZEH1 at an MOI of 0.1 and harvested at times 
post infection.  * P < 0.05, ** P < 0.005 
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3.3 DISCUSSION 
In this chapter, the production of highly replication-defective HSV-1 vectors was 
addressed by characterizing the kinetics of RNA and protein expression from cell-based 
complementing genes for a highly mutated vector, JDTOZHE, compared to the expression of the 
same genes from the wild type virus genome.  Replication-defective vectors are useful for 
nontoxic delivery of therapeutic transgenes, but these viruses lack essential functions for 
autonomous propagation which must therefore be supplied in trans.  Constitutive cellular 
expression of these essential functions is cytotoxic, thus preventing the healthy growth and use 
of cell lines modified in this manner.  This problem has been overcome in the past by using 
inducible promoters that are responsive to viral infection, such as the HSV-1 IE promoters (152).  
On infection with the defective virus, these promoters ideally direct expression of the missing 
gene products with the same kinetics and to the same levels as in wild-type virus infections.  
However, since the complementing genes are provided by the cell, their numbers will not 
increase on infection, unlike their viral counterparts in wild-type virus infections which are 
amplified by viral genome replication.  Thus, it is likely that defective virus grown with the 
assistance of cell-based complementing genes will have a lower replication ceiling than wild-
type virus.  This provides a simple explanation for the common observation that complementing 
genes integrated in the host cell genome do not restore defective virus growth to the levels 
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achieved by wild-type virus.  Since this deficiency directly reflects limiting levels of the 
complementing gene products, designs to increase expression of the complementing genes will 
be beneficial.  However, the generation of such complementing cell lines remains a challenge 
due to the lack of control over the number of complementing genes that will integrate or their 
position in the cellular genome; both of these variables affect expression. While viral vector 
systems exist that do provide a degree of control over these parameters, these systems introduce 
additional genetic material into the cell which is undesirable.  Compounded with this drawback 
is the issue of complementation stability for the purposes of cell banking for large scale 
production.  Additionally, as pointed out in this work, the complementation efficiency can 
drastically alter the production of replication defective vectors which becomes more critical as 
the vector needs more gene products to be supplied in trans. 
Vector backbone will also effect vector yields as more essential viral functions are 
removed growth phenotypes can be dramatically reduced.  Certain multiplicities of infection 
(MOI) will dictate how an infection can proceed (133).  As the genotype of the virus is depleted 
of essential gene functions higher MOIs are necessary to grow high titer virus.  This strategy, 
however, can severely limit large scale production since higher amounts of input virus is needed.  
Likewise, the backbone of the virus will influence what type of complementing cell line is 
necessary for growth.  ICP0 mutants grow poorly in standard approved cell types (Vero, Hep-2, 
etc) but an osteosarcoma cell line, U2OS, are highly permissive for reasons yet to be determined 
(202). Likewise, ICP22 mutants grow poorly in rabbit skin cells but have normal growth 
phenotype in Vero cells (17).  Optimal cell line construction is therefore critical for propagation 
of different mutants depending on their intended use for in vivo gene transfer. 
By increasing the level and efficiency of complementation, we have shown that the 
production of more disabled versions of replication defective mutants of HSV-1 can be improved 
dramatically.  Other studies that have examined the culture conditions and genetic background 
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for production of double (ICP4 and ICP27 negative) and triple (ICP22, ICP4, and ICP27 
negative) mutant HSV-1 strains suggest that scale up be the ultimate solution for production of 
large scale quantities of replication defective HSV-1 vectors (133).  The use of microcarrier 
based bioreactors has also been shown to increase overall yield for double HSV-1 mutants as 
well as Vaccinia virus, however, this system has not been explored for the growth of a more 
deleted vector (12, 181).  The authors of this work found that as the virus became more defective 
the productivity dropped off due to lack of complete complementation.  We have shown here that 
by engineering the architecture of the promoter to incorporate the essential viral functions, a 
better yield per cell could be achieved.  Increased expression of ICP4 presumably not only led to 
higher levels of early and late classes of genes but may serve as a protection function in the 
stability of the viral genome as evidenced by enhancement in total HSV-1 genome copy number 
(173, 174).      
There are noticeable differences in RNA translation and protein expression with respect 
to ICP4 where the RNA levels are quite low in the case of the 4d4 cells but the protein 
expression occurs only after 9 hours post infection.  In the case of 0d4 cells the earlier RNA 
transcription presumably led to earlier translation into functional ICP4 protein levels detected by 
western blot analysis.  A possibility for this discrepancy in RNA:protein correlation is that the 
overall copy number of ICP4 has not reached a critical threshold until 7 to 9 hours post infection 
in these complementing cell lines.  In the absence of functional ICP4 there is a significant deficit 
in transcriptional capacity as which can lead to deficits in translation capacity as well since this 
gene product represents the major transactivator of the virus.  Another possibility is a disjointed 
cascade of viral gene regulation without sufficient ICP4 expression which could lead to 
overexpression of viral genes that are normally repressed by ICP4.  Additionally, lack of ICP4 
can lead to inefficient replication compartments since localization of ICP0, ICP27, and ICP4 has 
been shown to occur concomitantly with HSV-1 viral DNA replication (50).  
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Future work on viral genome and ICP4 localization may shed light on the 
complementation of ICP4 from a cell line versus the natural infection and its ability to enhance 
stability.  This work will serve to bolster future developments in the field of replication defective 
viruses such as safer vaccine candidates as well as support clinical applications for future gene 
therapy trials. 
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4.0  HSV-1 DEREPRESSION 
Herpes simplex virus 1 (HSV-1) is a common human pathogen. Following viral infection  
and release of the viral genome in the nucleus of permissive host cells, lytic infection starts a 
temporally regulated program of HSV-1 gene expression. The immediate early genes (IE) ICP0, 
ICP4, ICP22, ICP27, and ICP47 are first expressed and their products are required for expression 
of early and late HSV-1 genes (7, 21, 75, 76).   Among the five IE genes, only ICP0 is known to 
transcriptionally activate all kinetic classes of genes, i.e. the IE, early and late genes (86). 
HSV-1 contains genes classified as essential or non-essential, depending upon their 
requirement for viral replication in cell culture.  However, the so-called non-essential genes play 
critical roles in completion of the virus life cycle in vivo. Among the non-essential genes, ICP0 
is a multifunctional protein which regulates expression of a broad range of viral and cellular 
genes and proteins.  Interestingly, deletion of ICP0 gene alters viral gene expression in a cell-
type dependent manner.  Earlier studies on infection of Vero and U2OS cells with an ICP0 null 
mutant, 7134, showed that expression of the IE protein ICP4 and the early protein gD as well as 
plating efficiency of the mutant virus were significantly higher in U2OS cells than in Vero cells 
(202).   
The mechanism(s) underlying the difference in host cell responses that might contribute 
to the contrasting effects of ICP0 deletion in U2OS and Vero cells has not been defined. A 
plausible hypothesis is that untransformed cells contain an innate defense system that represses 
HSV-1 gene expression and the protein ICP0 counters this innate defense system to allow viral 
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gene expression and growth.  The evidence in support of this hypothesis comes from a recent 
study (67) in which somatic cell hybrids formed between the permissive U2OS cells and highly 
restrictive HEL fibroblasts were as non-permissive as HEL cells to infection with KM110 (a 
mutant that lacks ICP0 and VP16). These observations suggest that the cellular mechanism 
responsive to ICP0 deletion is important in viral gene expression and, possibly, in tumor growth. 
One of the reasons for the slow progress in defining this mechanism has been the scarcity of 
chemical agents that mimic the effects of ICP0 on gene expression.   This chapter describes the 
use of a cell-based, rapid, and simple fluorescence assay for a chemical screen to identify 
compounds that might be important for defining the repressive cellular mechanism that is 
negated by ICP0 expression.  
 
4.1 INTRODUCTION 
HSV-1 represents an attractive vehicle for gene transfer applications in vitro and in vivo.  
A number of facets of HSV-1 biology affirm its utility which include the large genome (84 open 
reading frames) of which half is non essential, ease of manipulation, and latent state of infection 
for long term therapy.   Naturally occurring infections within the nervous system also make 
HSV-1 attractive for neuropathies as well as glioma therapy (25, 128).  Replication defective 
HSV-1 vectors have been used for gene transfer in numerous disease states in different tissue 
models (77, 97, 160).  These vectors lack essential IE genes which render them nontoxic and safe 
for clinical application.  Removal of the IE genes will block expression of the virus lytic gene 
program in non-neuronal cells and therefore transgene expression is severely repressed.  
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However, viral genomic repression in the quiescent model can be relieved by expression of a 
single IE gene, ICP0 (44, 116).    
 HSV-1 mutants that fail to express ICP0 have severe defects in viral gene expression and 
plaque formation in mammalian cells (16, 52, 63).  Despite this critical importance in virus 
propagation, ICP0 severely reduces cell viability and will induce cell cycle arrest (34, 74).  
Additionally, the E3 ligase activity attributed to the RING finger domain of ICP0 has been 
shown to degrade host cell responses to infection (13, 14, 100).  These cell responses include 
accumulation of nuclear organelles which are associated with chromatin reorganization such as 
PML, Daxx, and Sp100 (2, 49).  This effect is clearly marked by punctuate structures associated 
with nuclear domains (ND10) and ICP0 can effectively degrade these structures in a RING 
finger dependent manner (51).   However, in certain tumor cell types (e.g U2OS) ICP0 is not 
required for transgene function and in fact ICP0 deletion mutants grow efficiently in these cells 
and are similar to wild type with respect to virus yields.  Thus, U2OS cells appear to be defective 
in one of more cellular functions that repress the viral genome. This is likely to be a missing 
function based on fusion of non-permissive HEL cells with U2OS in which the fusogenic 
progeny were still non-permissive (67).  Studies to examine the mechanisms underlying the 
permissive effect of U2OS cells suggest that they possess an ability to complement ICP0 
deficiency (166, 202).  However, it is not clear whether this is a direct effect as no molecular 
mechanisms are currently known.  The basis for this interaction has critical importance in cancer 
therapy as well as HSV-1 biology.  
We report the use a high throughput cell based assay for detection of potential agonists 
that can lead to derepression of HSV-1 genomes in the presence of a non-permissive cell 
environment.  The LOPAC (library of pharmacologically active compounds) library was chosen 
for the screen due to the well documented activities of each of the compounds.  Vero cells 
preincubated with the LOPAC library and subsequently infected with a quadrurple IE mutant 
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QOZ22REH1 reveal novel interactions of host cell state that can allow expression of EGFP from 
the HCMV promoter which is otherwise silent during normal infection.  A metal chelator, 1,10 
phenanthroline monohydrate, was the only compound that could release Vero induced repression 
while maintaining a low cytotoxicity profile.  The induction of a novel RING finger protein 
termed sensititive to apoptosis gene (SAG) was observed in the presence of 1 10 phenanthroline 
both with and without infection suggesting a potential role of this gene in depression of the viral 
genome.  This gene has E3 ligase activity much like the viral gene ICP0 and serves as a potential 
derepressor of the viral genome in the context of an IE mutant infection.  Likewise, proteosome 
inhibition experiments reveal a common pathway for this gene and implicate the presence of a 
cellular protein or protein complex in Vero cells that can actively participates HSV-1 gene 
repression   
 
4.2 RESULTS 
4.2.1 Genetic Map of TOZHE and QOZH22REH1 
To assess the effect of ICP0 on the derepression of HSV-1 mediated delivery of a transgene in 
Vero cells two isogenic mutants were used.  The control virus, TOZHE, has the ICP0 gene intact 
but is devoid of ICP27, ICP22, ICP4, and UL41.  This virus is a progeny of TOZ.1 with the 
EGFP transgene driven by the CMV promoter in the ICP4 locus (193).  QOZ22REH1 is a 
quadruple IE mutant with EGFP driven by the HCMV promoter in the ICP0 locus.  Figure 19 
shows the genetic map of each vector. 
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Figure 19. Genetic Map of TOZHE and QOZ22REH1 
Schematic map of QOZ22REH1 and TOZHE.  The dsRed2 gene is driven by the ICP22 promoter 
in the ICP22 locus in QOZ22REH1.  EGFP driven by HCMV in the ICP4 locus in TOZHE and 
the ICP0 locus in QOZ22REH1.  QOZ22REH1 is propagated on the ICP0, ICP4, and ICP27 
complementing cell line 01.  TOZHE is propagated on ICP27 and ICP4 the complementing cell 
line Q5. X at a genetic locus indicates removal of this gene. 
4.2.2 Chemical Library Screen 
The LOPAC (library of pharmaceutically active compounds) was screened for potential 
derepressors of HSV-1 gene expression by gain of signal through EGFP expression.  Vero cells 
were plated in clear bottom, black walled 384 well plates in phenol red free media via a Titertek 
Zoom dispenser.  Twenty four hours post seeding cells were administered the LOPAC library via 
the Vprep mutichannel dispenser at 25 uM.  Two hours post-administration with the library, the  
monolayer was infected with QOZ22REH1 at an MOI of 3 based on transducing units in U2OS 
cells.  Three days post infection, the EGFP signal was assessed by visual confirmation.  
Pretreatment with 1 10 Phenanthroline (OP) was able to give rise to adequate EGFP expression 
compared to the control vector (Figure 20).  Previous reports indicate that histone deacetylase 
inhibitors can relieve cellular repression during quiescence from an HSV-1 mutant devoid of any 
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IE gene function (179).  In contrast, pre-incubation with TSA at effective concentrations for 
growth enhancement of triple mutant viruses yielded no significant increase in EGFP expression 
from the QOZ22REH1 backbone.   
QOZ22REH1
25 uM 
1 10 Phenanthroline
QOZ22REH1
No Drug
QOZ22REH1
400 nM 
TSA
TOZHE
QOZ22REH1
U2OS Cells
1 10 Phenanthroline
N N
 
Figure 20. 1 10 Phenanthroline Aids in EGFP Expression  from QOZ22REH1.   
Confocal fluorescent microscopy of Vero (top row and TOZHE) and U2OS (QOZ2REH1 without 
drug) monolayers either untreated or pretreated with drug at indicated doses for one hour prior to 
infection.  Chemical structure of 1 10 Phenanthroline. 
 QOZ22REH1 transgene expression in U2OS cells was similar to TOZHE expression in Vero 
cells consistent with previous reports suggesting this cell line can substitute for a functionality 
expressed by ICP0 (202). 
4.2.3 Proteosome Pathway Dependency 
The proteosomal pathway is a critical component for HSV-1 derepression as evidenced by ICP0 
specific degradation of innate cellular response to infection (52, 65).  To this end, the effect of 
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proteosome inhibition was examined for derepression of QOZ22REH1 either alone or in 
combination with 1 10 phenanthroline (referred to as OP from here on).  In the presence of 
MG132 the expression of EGFP was significantly altered in both U2OS and Vero cells (Figure 
21). 
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Figure 21. OP Mediated Derepression is Proteosome Dependent 
Fluorescence microscopy of EGFP 72 HPI from QOZ22REH1 (MOI = 3) in either OP pretreated 
(OP), MG132 pretreated (MG132), or OP pretreatment followed by MG132 pretreated (OP 
MG132) U2OS or Vero cells. 
The marked difference in EGFP expression in presence of the proteosome inhibitor MG132 
indicates that HSV-1 mediated gene expression from the viral backbone is dependent on this 
pathway.  Furthermore, OP pretreated Vero and U2OS cells were still able to express EGFP from 
the viral genome in the presence of MG132 suggesting possible degradation of a repressive 
protein before proteosomal inhibition in both cell types.  However, higher viral transgene 
expression with both OP and MG132 in U2OS cells indicates cell type specificity for this 
interaction.  These data support the hypothesis of the induction of a novel gene product or 
pathway upon OP administration. 
In a similar manner, TOZHE was examined for EGFP expression in the presence of MG132 and 
OP or a combination thereof. 
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Figure 22. ICP0 Mediated Transgene Expression blocked by MG132 but not by OP 
Fluorescence microscopy of EGFP 72 HPI from QOZ22REH1 (MOI = 3) in either OP pretreated 
(OP), MG132 pretreated (MG132), or OP pretreatment followed by MG132 pretreated (OP 
MG132) U2OS or Vero cells. 
The induction of EGFP from the TOZHE backbone was independent of OP regimen but 
significant reduction in signal in the presence of MG132 is consistent with reports on the E3 
ligase activity of ICP0 through the proteosomal pathway.  Interestingly, U2OS cells also 
displayed a dependency on the proteosome pathway for EGFP expression indicating the 
degradation of a native moiety involved in HSV-1 genome repression in this cell line. 
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 4.2.4 MOI and OP Dose Response 
To further examine the sensitivity of the OP mediated effects of derepression on HSV-1 
mediated transgene expression, a dose escalation with input virus and OP was performed on 
Vero cells.   
MOI = 30
OP 
No 
Drug
MOI = 3 MOI = 0.3 MOI = 0.03
A.
B.
100 uM 10 uM 1 uM No Drug  
Figure 23. MOI and OP dose response with QOZ22REH1 
A. Fluorescence microscopy of Vero cells pretreated with 25 uM OP subject to infection with  
QOZ22REH1 at MOIs indicated. B. Dose escalation of OP.  Vero cell were pretreated with 
concentrations of OP indicated and infected with QOZ22REH1 at MOI = 3. 
The enhanced fluorescence at higher MOIs reflects the sensitivity of the pretreated cells to the 
increasing input viral genomes.  Generally, higher input doses of virus can overcome limitations 
in gene expression for IE mutants, however, this was not the case in absence of OP up to an MOI 
of 30.  This data suggest a strict requirement of cell state to enhanced viral transgene expression 
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in the absence of all IE genes.  Dose response to OP concentration revealed effective phenotype 
reversal at micromolar concentrations.  The lower fluorescence at 100 uM OP is indicative of 
cytotoxicity of this compound at higher concentrations.  These data suggest that OP is effective 
in manipulation of host cell state to allow HSV-1 mediated transgene expression at moderate 
MOIs.  Furthermore, the dramatic enchancement of EGFP expression at higher MOIs suggest 
that the OP pretreatment is the limiting factor in derepression since increasing the number of 
incoming viral particles was not able to overcome this effect in the absence of OP treatment.   
4.2.5 Senstitive to Apoptosis Gene (SAG) Induction 
Previous reports protection from peroxide and free radical induced DNA damage have suggested 
that the gene termed sensitive to apoptosis gene (SAG) is expressed with rapid kinetics in both 
kidney and liver tissue upon stimulation with 10 uM OP (43, 175).  Cell lysates collected from 
the monolayers shown in Figure 21 were assayed for SAG expression by western blot analysis.  
SAG was enhanced in Vero cells upon normal growth in 25 uM OP (Figure 24 Mock Lanes).   
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Figure 24. SAG induction upon 25 uM OP culture 
A. SAG expression in Vero cell lysates from Figure 22 and 23 were separated on 12% SDS-
PAGE blotted for SAG.  ND refers to no drug.  QOZ22REH1 and TOZHE (MOI = 1) 
Infections were lysed at 24 HPI. B. SAG expression in U2OS cells infected either Mock or 
QOZ22REH1 MOI = 3. 
SAG bands present in all lanes infected with TOZHE implies that this gene is protected from 
degradation by the expression of ICP0 and may serve to aid in gene expression from the virus 
backbone.  Increased expression in cultures exposed to MG132 imply that this gene may be 
degraded by the presence of viral genomes in the absence of ICP0 (QOZ22REH1 lanes in Figure 
24).  However, a diminished band at 24 HPI in the presence of OP alone (Figure 24 A 
QOZ22REH1 OP) suggests that at this time point the gene may be active but further degraded at 
later times post infection.  Furthermore, U2OS cells displayed little dependency on OP treatment 
or infection status for SAG expression indicating this protein is constitutively expressed in this 
cell line (Figure 24 B).  These data suggest that the induction of SAG and its expression during 
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derepression of the HSV-1 genome may be a novel mechanism for overcoming the innate barrier 
to viral gene expression. 
4.3 DISCUSSION 
HSV-1 infects a high percentage of any population groups, commonly causing skin and 
mucosal lesions only in a fraction of actual infections.  Thus, HSV-1 has coevolved with its 
human host and is rarely life-threatening in immunocompetent individuals.  This characteristic 
makes HSV-1 an attractive platform for therapeutic vector development. Furthermore, HSV-1 
efficiently infects a wide variety of cell types and the genome has numerous non-essential genes 
whose deletion allows insertion of large transgenes.  However, deleting genes from a genome 
that evolved to survive in a hostile niche weakens the vector and tilts the balance in virus-host 
cell interactions in favor of the repressive mechanisms in the host cell.  Transgene expression 
from ICP0-null mutants in normal cells is inefficient making such vectors of limited 
applicability.  Unraveling the molecular basis of how ICP0 negates repression of gene expression 
in normal cells and why ICP0 is dispensable in a tumor cell microenvironment is of fundamental 
importance to our understanding of regulation of eukaryotic gene expression.    
Immediately upon release of HSV-1 DNA from capsids, a competition ensues between 
cellular factors whose mission is to silence viral DNA and viral proteins that aim to block the 
cell.  The innate immune response has been well documented as an active repressive mechanism 
for viral gene expression (30, 100).  ICP0 as a preemptive viral defense mechanism effectively 
counteracts this response through degradation of key antiviral cellular organelles (52).  The E3 
ligase functionality is essential for this function of ICP0 indicative of exploitation of the 
proteosomal pathway.   
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Efficient infection by ICP0-negative mutants is not limited to cells with a deregulated 
interferon system.  Although ICP0 deletion mutant 7134 (202), displayed reduced plating 
efficiency in Vero cells at low multiplicities of infection, it grew efficiently in the osteosarcoma 
cell line U2OS. Furthermore, Western blot analysis showed that the levels of expression of the 
IE protein ICP4 and the early protein gD in 7134-infected U2OS cells were significantly higher 
than those in 7134-infected Vero cells.  Similar to 7134, a mutant that lacks functional ICP0 and 
VP16, KM110, is impaired for growth in primary human fibroblasts, but replicates efficiently in 
U2OS cells (122).  The underlying mechanism for the contrasting expression patterns of 7134 
and KM110 genes in restrictive and permissive cells is not known.  One possibility is that U2OS 
cells express stimulatory factors that complement ICP0 and VP16 deficiency (202); another is 
that the permissive U2OS cells lack a repressive mechanism that is targeted by ICP0 which has 
not been explored.  To distinguish between these two possibilities, hybrid cells formed by fusing 
the permissive U2OS cells with the highly restrictive human embryonic lung (HEL) cells were 
infected with KM110. The heterokarya were completely non-permissive for KM110 IE gene 
expression, indicating that restrictive cells contain one or more rapidly acting dominant 
inhibitory factors that are absent from permissive U2OS cells (67).  Additionally, HSV-1 
repression has been studied extensively through latency and quiescence in the neuronal as well as 
other tissue models (29, 116, 179).  The current understanding is a mechanism of 
heterochromatin state within the immediate early viral gene promoters preventing the toxicity of 
these genes (29).  However, deregulation of this repression mechanism through small molecule 
inhibitors is yields only moderate recoveries implicating multiple repressive phenomena (see 
Chapter 3 section 3.2.3)   
The mutant we have developed, QOZ22REH1, lacks functional ICP0, ICP4, ICP22 and 
ICP27 and contains EGFP under the control of HCMV.  Unlike the mutants described above, 
7134 and KM110, QOZ22REH1 is a highly defective non-replicating vector that fails to express 
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any viral gene products.  This vector represents an important tool for investigating regulation of 
viral gene expression, independent of the process of viral replication. Consistent with the 
findings described above, we have observed that expression of exogenous enhanced green 
fluorescent protein (EGFP) reporter gene is repressed in Vero cells but not in U2OS cells.  A cell 
based high throughput chemical library screen allowed the identification of a potent compound 
(1 10 phenanthroline) which negated gene silencing in Vero cells to enable efficient expression 
of exogenous genes inserted in the highly defective HSV-1 mutant vector QOZ22REH1.  The 
derepression was specific to the host cell state induced by this compound (Figure 23) and was 
dose responsive to input virus.   Interestingly, at high multiplicities this mutant vector was only 
available to overcome genomic repression in the presence of drug suggesting a cellular factor 
that was either degraded or induced upon drug administration.  Studies with the proteosome 
inhibitor MG132 showed that this effect was slightly reduced in the absence of proteosome 
activity suggesting that this pathway was essential for viral transgene derepression.  More 
importantly, this effect was also observed in U2OS cells indicating the presence of a cellular 
factor involved in active repression whose gene product was not degraded in the presence of 
MG132.  This gene product has yet to be defined but future experiments outlining the 
mechanism perhaps through microarray studies will shed light on this previously unknown 
function. 
  Previous studies have shown that administration of OP to cell cultures will induce the 
presence of the gene termed sensitive to apoptosis gene, SAG(43).  This gene product much like 
ICP0 contains a zinc RING (Really Interesting New Gene) finger domain that has been 
demonstrated to exhibit E3 ligase activity indicating that it could represent a novel target of some 
repressive function that inhibits viral gene expression (69, 176). The presence of this gene was 
consistent in all infections that retained the derepressed phenotype of allowing EGFP expression 
from the viral genome.  In addition, induction of SAG was shown to be sensitive to OP treatment 
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in Vero cells as assayed by western blot.  Interestingly, in Vero cells infected with QOZ22REH1 
the SAG expression was neglible at the resolution of this assay without drug treatment.  This 
could indicate the necessity of this gene product to the derepressed phenotype of the IE mutant 
backbone.  More importantly, SAG was present in all conditions examined with U2OS cells 
indicating that this gene may play a role in the permissive nature of this cell line.  This is the first 
report indicating the presence of a novel gene involved in the proteosomal pathway that can lead 
to enhanced gene expression from an HSV-1 mutant devoid of any IE function.  Future 
experiments investigating the interaction partners and proteosomal targets of this gene will 
elucidate   
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5.0  ION EXCHANGE PURIFICATION OF HSV-1 VECTORS 
Purification of clinical grade viral based gene therapy products must adhere to strict FDA 
requirements with respect to contaminating host cellular DNA and protein.  In addition, these 
processes must be scaleable to meet the demand for early phase trials.  Common methods of 
purification for viral vectors include sucrose and cesium gradients, ultracentrifugation, as well as 
immobilized metal affinity chromatography (IMAC) (90).  These strategies are suitable for 
bench scale production, however, translation to industrial scale is difficult for specific reasons to 
each application.  Gradient centrifugation is costly and not readily amenable to large scale use 
due to specialized equipment and low yields.  Ultracentrifugation, while scalable, can aggregate 
contaminating cellular debris along with virion particles.  IMAC chromatography while 
improving yields and specificity requires further manipulation of the viral backbone which can 
add unnecessary complexity to the purification scheme and time to the development process.   A 
common purification strategy for all backbones would greatly benefit the translation of HSV-1 
gene therapy into the clinic.  HSV-1 is an enveloped DNA virus that requires gentle separation 
methods so as not to rupture the glycoprotein coat and render the virion non-infectious.  Taking 
these considerations into account, an ion-exchange strategy is proposed that takes advantage of 
the robust nature of charge-charge based separation along with the freedom to manipulate 
loading conditions.  Described is an investigation into loading conditions using both ion and 
anion exchange chromatography to purify wild-type HSV-1.  By optimizing loading conditions, 
yields were increased by orders of magnitude.  Furthermore, HSV-1 affinity differences between 
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anion and cation exchange chromatography lead to these differences in recoveries.  Additional 
developments are also suggested.  
 
5.1 INTRODUCTION 
Substantial progress in the field of viral mediated gene therapy has resulted in increased pressure 
to develop methods for large scale production of high titer vectors free of host cell contaminants 
which can induce immunity and therefore decrease the effectiveness of the gene delivery.  In 
addition to purity, downstream process concerns include total injectable volume, mass transfer 
effects, and specificity.   For genetic manipulation of the central nervous system, there is a lack 
of space for large deposits.  The volumes of purified stocks must therefore be minimized to 
enable efficient spread of the virus to only the tissue of interest.  High speed centrifugation is 
commonly used to crudely purify viral vectors, but this method lacks specificity for the virus and 
can co-sediment host cell protein as well as DNA (27).  Sucrose gradients are also employed to 
sediment the virus based on density.  This method is attractive in that genome containing virions 
are separated from empty capsids (126).  However, large shear effects are often encountered in 
high speed centrifugation through sucrose gradients and this strategy is not amenable to large 
scale operation (149).  These shear effects become more critical with respect to enveloped 
virions since they are generally more labile.   Therefore, column based chromatography remains 
the separation method of choice that allows scalability as well as freedom to dictate the relative 
concentration of the virus by controlling elution conditions.  Loading conditions can be 
optimized to avoid mass transfer effects by adjusting flow conditions.  For instance, the mass 
transport limitations can be overcome by loading at higher flow rates but this phenomenon must 
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be balanced by the shear sensitivity of the virus.  More importantly, specificity can also be 
obtained to tailor the separation based on resin density and molecular characteristics (88).  The 
development of ion exchange based chromatography to purify enveloped as well as non-
enveloped gene therapy viral vectors has been well established (60, 88, 198).  While adenoviral 
vector purification remains an active area of research due to the prevalence in clinical trials, there 
is limited work on chromatographic purification of HSV-1 based viral vectors.  The work to date 
consists of either targeting the virus to a ligand based separation such as IMAC (82) or affinity 
adsorption (129).  These techniques are not limited to purification of HSV-1, however, and have 
been used to produce retroviral (204), adenoassociated (206) and lentiviral vectors (163). 
In this chapter, we describe the use of ion exchange chromatography to purify wild type 
strain of HSV-1, Kos.  Infectious virus losses experienced on both anion and cation exchange 
columns were significant and most likely due to inactivation or irreversible binding to the 
column matrix.  Among all pH conditions tested physiologic pH yielded higher recoveries on 
both columns.  However, the cation exchange column was able to provide higher yields due to 
lower affinity for the virus.  This was verified by investigation of loading virus at elevated NaCl 
conditions.  The higher salt concentrations effectively competed off the virus to both columns 
albeit with higher efficiency in the anion exchange column.  Likewise, yields of both ion 
exchange strategies were compared with respect to DNA encapsidated virions and genomic copy 
number.  The cation exchange column was able to purify virus with higher concentration of 
genome containing virions as verified by electron microscopy as well as quantitative PCR for 
genome copy number.  Electron microscopy validated these results showing higher concentration 
of genome containing virions in the cation exchange elution  Loading condition experiments 
reveal a dose response with flow rate suggesting that the mass transfer limitations are minimal 
for both cation and anion exchange chromatography.  Additionally, the total protein content was 
substantially lower in the eluted fractions compared to loaded material suggesting that cation 
 85 
exchange with physiologic pH can yield relatively pure virions that are suitable for clinical 
applications.  .  
5.2 RESULTS 
5.2.1 Cation and Anion Exchange Chromatography Purification of HSV-1 
Ion exchange chromatography was explored as a technique for purification of wild type KOS.  
This vector was crudely purified by high speed centrifugation outlined in chapter 2.  This stock 
was tested for infectious virus recovery in both anion and cation exchange chromatography to 
investigate binding properties.  Kos was loaded onto HiTrap ion cation (SP) and anion (Q) 
exchange columns at 0.5 ml/min driven by a P1 pump.  All samples were loaded at physiologic 
pH in 1X PBS at room temperature.  Fractions labeled flow through (collected as the virus was 
loaded), wash (a 5 column volume wash in 1X PBS), and elution (pooled elution of 9 column 
volumes of 0.45 M NaCl). Viral recoveries as measured by plaque assay on Vero cells are shown 
in Figure 25 for the anion exchange column.   
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Figure 25. Infectious virus recovery with anion exchange chromatography 
1E9 PFU of Kos was loaded at 0.5 ml/min at pH = 7.0 in 1X PBS.  Elution was performed at 0.45 
M NaCl.  Fractions were assayed for infectious virus by titration on Vero cells.  Error bars are 
indicative of three independent experiments. 
 
Viral recoveries are dramatically low with little to no infectious virus appearing in the wash or 
flow through fractions using this ion exchange strategy.  Likewise, recoveries in the elution are 
substantially low compared with input.  Since this column matrix is positively charged, these 
results suggest that the either virus binds with high affinity and at physiologic pH may be 
negatively charged or the virus may inactivated within the column matrix.  A high salt (1 M 
NaCl) elution was performed to assess the relative binding strength of HSV-1 to this column 
matrix.  Figure 26 shows the enhanced recovery with this elution scheme, however, a higher 
contaminating protein level (Table 2) was also experienced compared to the 0.45 M NaCl 
elution.  SP column elution at higher salt concentration was not explored since the higher 
contaminant level would not be satisfactory for clinical grade virus. 
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Figure 26. Elevated salt dependency for efficient elution from anion exchange chromatography 
1E9 PFU of Kos was loaded at 0.5 ml/min at pH = 7.0 in 1X PBS.  Elution was performed at 1.0 
M NaCl.  Fractions were assayed for infectious virus by titration on Vero cells. Error bars are 
indicative of three independent experiments. 
To investigate these results further, genomic content was assayed by quantitative PCR for the 
same samples presented in Figure 25.  Genomic recoveries in the flow through and wash 
fractions are enhanced as compared to infectious virus indicating the presence of contaminating 
DNA from the cellular debris that has cosedimented during the high speed centrifugation.  The 
dramatically high amount of genomes in the elution suggest that viral DNA is bound to the 
column in addition to infectious virus and could possibly compete for binding sites.      
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Figure 27. Genomic recovery from anion exchange chromatography 
PCR quantitation of viral genomes from Figure 26.  Error bars are indicative of three 
independent experiments. 
    
Cation exchange chromatography was evaluated similarly as for anion exchange 
chromatography.  Infectious virus recovery for cation exchange was dramatically improved with 
cation exchange chromatography in all fractions tested (Figure 28).  The wash and flow through 
titers indicate weak binding of the virus to this exchange media.  Eluted virus recoveries were 
also enhanced compared to anion exchange further indicating a weaker association within the 
cation exchange matrix.  However, significant losses were experienced in all fractions tested 
suggesting that the virus could be inactivated within this ion exchange media as well. 
Genomic recoveries from cation exchange chromatography were assessed similar to 
Figure 26.  Approximately 20% of the input genomes were recovered in the elution fraction 
(Figure 29).  Likewise, in comparison to anion exchange, there was enhanced recovery in the 
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wash and flow through fractions further suggesting weak association of the viral genome with 
the negatively charged resin. 
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Figure 28. Infectious virus recovery from cation exchange chromatography 
1E10 PFU of Kos was loaded onto the cation SP resin at flow rate of 0.5 ml/min and pH = 7.0 in 
1X PBS.  Elution was performed at 0.45 M NaCl. Error bars are indicative of three 
independent experiments. 
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Figure 29. Genomic recovery from cation exchange chromatography 
Quantitative PCR analysis from fractions in Figure 28.  Error bars are indicative of three 
independent experiments. 
The consistent excess genome copy numbers relative to infectious virus (PFU) indicate there are 
defective interfering particles that can co-elute from the ion exchange columns.  Additionally, 
this viral DNA can originate from either co-sedimentation (during high speed centrifugation) or 
viral DNA that is adherent to the virion particles themselves.  These sources of viral DNA can 
contaminate the virus stock prior to loading onto the ion exchange columns. 
5.2.2 Proton Concentration Effect on Loading Conditions of Ion Exchange 
Chromatography 
 Proton concentration in the load buffer was investigated to assess whether or not there would be 
a possible pH effect on virus binding to each ion exchange resin.  The same flow rate as in 
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Figures 25-29 was chosen to investigate pH loading conditions.  Figure 30 shows the overall 
recoveries at moderately alkaline loading conditions (pH = 8.0) versus slightly acidic (pH = 5.0)  
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Figure 30. Proton concentration effect on infectious recovery from ion exchange chromatography 
Kos equilibrated in either pH = 8.0 or 5.0 loaded onto either (A) cation exchange or (B) anion 
exchange chromatography.  Virus was delivered at a flow rate of 0.5 ml/min.  PFU was assayed 
by titration of virus on Vero cells.  Error bars are indicative of three independent 
experiments. 
 
Similar to Figures 25-29, the anion exchange column yields were substantially lower regardless 
of loading conditions.  In contrast, pH values appear to dictate the binding efficiency in the 
cation exchange column however overall infectious recoveries were still quite low.  From the 
preceding figures, it is clear that regardless of loading pH or resin choice significant infectious 
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virus losses are experienced.  However, cation exchange resins appear to be able to recover virus 
at higher titers due to lower binding affinity.  To further investigate these claims, electron 
microscopy was undertaken to examine the structural features of the viral recoveries.   Figure 31 
shows the input virus before dilution and delivery into the column. Figure 32 reflects both a 
higher concentration of total virions with the cation exchange as well as higher fraction of full 
capsids as obtained by negative staining with uranyl acetate.  
 
Figure 31. TEM of pelleted virus 
1E9 PFU of Kos diluted in 8 ml of 1X PBS stained by uranyl acetate.  Scale bar indicates the size 
of virions.  Dark virions are empty capsids.  White or light colored virions are genome containing 
virions. 
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Figure 32. TEM of eluted virus from anion and cation exchange chromatography 
Purified virions were diluted 1:1 in water and stained with uranyl acetate.  A. Cation (SP) 
exchange puirifed virions. B. Anion (Q) exchange purified virions 
 
5.2.3 Flow Rate Effect on Loading Conditions of Ion Exchange Chromatography  
Mass transfer effects were investigated by varying the feed flow rate into both anion and cation 
exchange column chromatography.  As observed in our laboratory, both columns have 
previously been shown to bind the virus and are able to purify vectors.  A systematic 
investigation, however, has not been performed with respect to optimal loading conditions.  
Typical chromatographic flow rates for HSV-1 purification range from 0.5-0.7 ml/min (82, 129) 
but process economics factors in for larger batches.  Thus, faster processing of larger batches 
with similar recoveries would be dramatically advantageous in the face of time critical 
applications such as vaccinations for new mutations within pandemic strains.  
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Figure 33. Infectious virus recovery dependency on flow rate in anion exchange chromatography 
Infectious virus titered on Vero cells at various flow rates of loading virus at pH = 7.0 1X PBS. 
Error bars are indicative of three independent experiments. 
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Figure 34. Genomic recovery dependency on flow rate in anion exchange chromatography 
PCR quantitation of HSV-1 genomes obtained from samples in Figure 33.  Error bars are 
indicative of three independent experiments. 
 
Slight recoveries were experienced at lower flow rates for anion exchange chromatography but 
overall this effect is neglible in comparison to total input virus.  However, higher flow rates lead 
to lower genomes recovered (Figure 34).  This indicates that there is inactivation within the 
column matrix as the virus binds and flows through.  Likewise, the genomic recovery in the 
elution was around 2 orders of magnitude in comparison with the input virus at the lowest flow 
rate while the infectious recovery displayed a 4.5 order of magnitude differential at this flow 
rate.  The lower flow rate correlation with higher recovery suggests that optimal loading 
conditions for anion exchange chromatography are limited by the binding characteristics of the 
virus. 
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Figure 35.  Infectious virus recovery dependency on flow rate in cation exchange chromatography 
Infectious virus recovered at various feed rates assayed by titration on Vero cells.  Error 
bars are indicative of three independent experiments. 
Cation exchange chromatography flow rate dependency was evident in the flow through and 
wash fractions but not the elution fractions suggesting that the kinetics of binding to the column .  
The elution profile for all flow rates was relatively unaffected even though nearly two orders of 
magnitude differentials were realized in both the flow through and load indicating an inactivation 
event within the column since potentially more virus is bound at lower flow rates.  Likewise, 
there is substantial loss experienced within this strategy when comparing input virus and eluted 
yields which implicates inactivation within the column or irreversible binding.  To explore this 
last point further, genomic data was gathered as described in Figure 35.  Figure 36 shows 
enhanced genomic recovery at higher flow rates in the flow through albeit at a lower level than 
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the load fraction indicating that the virus is not binding as strongly at higher flow rates to this 
negatively charged resin.   
SP (Cation Exchange) Genomic Recovery Flow Rate Dependency
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+11
1.00E+12
Input FT Wash Elution
Fraction
H
SV
-1
 G
en
om
es 0.5 ml/min
1 ml/min
2 ml/min
5 ml/min
 
Figure 36. Genomic recovery dependency on flowrate in cation exchange chromatography 
PCR quantitation of HSV-1 genomes obtained from samples in Figure 36.  Error bars are 
indicative of three independent experiments 
The data point to a strong affinity of the virus for the anion exchange resin with weak binding to 
the cation exchange resin.  Taken together, these date indicate that there is little effect of flow 
rate on either ion exchange resin with respect to eluted infectious virus recovery.  These 
experiments also suggest that loading conditions are not the limiting factor in virus recovery and 
elution conditions may be limiting as evidenced by Figure 26.  
Table 2 highlights the protein and DNA concentrations for all experiments performed with both 
ion exchange resins indicating that there was significant improvement in contaminating protein 
and DNA with all conditions tested adhering to current FDA regulations with regard to cellular 
contaminants per dose. 
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Table 2. Protein and DNA Contamination level from Cation and Anion Exchange Chromatography 
  Input  Elution  
% 
Reduction  
 Q (anion) 
DNA 
(ug/ml) 
Protein 
(ug/ml) 
DNA 
(ug/ml) 
Protein 
(ug/ml) DNA Protein 
pH = 7.0 
Flow Rate 0.5 
11.92 +/- 
0.18 
183.4 +/- 
18.07 
0.065 +/- 
4.2E-5 
2.47 +/- 
0.98 99 98 
 1 
11.99 +/- 
0.02 
194.8 +/- 
1.57 
0.000189 
+/- 1.55 E-
5 
4.83 +/- 
0.39 99 97 
 2 
11.53 +/- 
1.19  
194.1 +/- 
4.91 
0.000225 
+/- 1E-6 
6.77 +/- 
0.78 99 96 
 5 
11.90 +/- 
0.15  
180.94 +/- 
17.6 
0.000185 
+/- 7E-6 
8.72 +/- 
1.96 99 94 
        
Flow Rate 
= 0.5 
ml/min pH 5 
9.37 +/- 
0.59 
196.77 +/- 
1.18 
0.0019825 
+/- 
0.00066 
5.94 +/- 
1.96 99 96 
 8 
11.5 +/- 
1.00 
196.08 +/- 
0.196 
0.0018 +/- 
0.0005 
4.13 +/- 
1.37 99 97 
1M Nacl 
Elution  
12.4 +/- 
0.86 
193.43 +/- 
4.73 
0.0123 +/- 
0.00454 48.83 99 74 
 
SP 
(cation) 
SP 
(cation)      
pH = 7.0 
Flow Rate 0.5 
11.57 +/- 
0.82 
196.08 +/- 
0.19 
0.0017 +/- 
0.0002 
2.47 +/- 
0.98 99 98 
 1 
12.34 +/- 
0.50 
194.83 +/- 
1.57 
0.00195 
+/- 7.07E-
5 
4.83 +/- 
0.39 99 97 
 2 
12.09 +/- 
0.16 
194.14 +/- 
4.9 
0.0012 +/- 
0.0003 
6.77 +/- 
0.78 99 96 
 5 
11.69 +/- 
1.01  
180.94 +/- 
17.6 
0.0017 +/- 
0.0001 
9.41 +/- 
0.98 99 95 
        
Flow Rate 
= 0.5 
ml/min pH 5 
10.93 +/- 
1.49 
180.94 +/ 
17.67 
0.00485 
+/- 0.0021 
9.41 +/- 
0.98 99 94 
 8 
11.75 +/- 
0.48 
192.05 +/- 
1.96 
0.00486 
+/- 0.01 
5.80 +/- 
2.16 99 96 
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 5.3 DISCUSSION 
HSV-1 is increasingly becoming the vehicle of choice for gene transfer within the central 
nervous system (68, 99, 172).  Treatments of neuropathic pain, glioma eradication, and sensory 
nerve damage have been well established in animal models and are soon to enter clinic.  To 
realize the potential of these applications, scalable manufacturing methods must be in place to 
provide high purity stocks devoid of any host cell contaminants that can potentially induce 
inflammatory responses to ectopic protein and DNA.  This chapter aimed at achieving an 
improved method for purification of HSV-1 that can provide high titer stocks that conform to 
current FDA standards for injectable biologics. 
Ion exchange chromatography has been used to purify viruses for a wide variety of 
applications (146, 184, 198).  Commercially available HiTrap columns are porous so the strategy 
of using these columns was investigated for obtaining high titer pure viral preparations to 
combine the selectivity of ion exchange with the fractionation capability of size exclusion.  
Anion exchange column liganded with quarternary amines were able to bind the virus with high 
efficiency at all flow rates examined indicating that the virus is highly negatively charged at 
physiologic pH.  Negligible dependency on flow rate on infectious virus recovery indicated that 
the binding efficiency was not altered by increasing the contact time within the chromatography 
media.  However, increased infectious virus recoveries in cation exchange chromatography 
suggest that this resin to be superior in purifying virus at elution in 0.45 M NaCl.  Cation 
exchange chromatography verified these results by yielding higher infectious virus at all flow 
rates examined in all fractions implying that the slight repulsion by negatively charged regions 
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within the glycoprotein coat could play a role in binding efficiency to either ion exchange resin.  
HSV-1 has been shown to exhibit altered electrophoretic mobility in the presence of different 
ionic buffers indicating that the glycoproteins are flexible with respect to ionization state and the 
loading conditions can be altered to selectively bind the virus to cation or anion exchange resins 
(185).  Additionally, it is well known that the virus mediates entry into host cells through 
interaction with heparin sulfate moieties and herpes virus mediators of entry (Hve) that are both 
positively charged (53, 187)  Furthermore, a synthetic polycationic peptide has been shown to 
bind to the glycoprotein C of the virus, which is necessary for cell surface heparin sulfate 
binding, suggesting that virus binding to the cation exchange column was most likely mediated 
through this glycoprotein and there are multiple binding modes of the virus to each ion exchange 
resin (186).  These results implicate a slightly negative charge surrounding the virion 
glycoprotein coat at physiologic pH with zones of positive charge that allow binding to the 
cation exchange resin. 
 Virus binding to both anion and cation exchange resins displayed no dependency on 
proton concentration while the recoveries in cation exchange showed dramatic differences with 
respect to the flow through and load fractions.  Slightly acidic conditions led to enhanced binding 
to the cation exchange resin suggesting that the overall virion charge may have been positively 
shifted under this loading scheme.  However, the binding to the anion exchange resin at this pH 
resulted in no infectious virus recovery indicating that other factors affected binding and elution.  
These factors include irreversible binding which could explain the low yield of infectious virus 
and total viral particles as demonstrated with electron microscopy.  The genomic data also reveal 
enhanced recovery from the cation exchange resin compared to anion exchange chromatography 
further validating the notion that virions could be irreversibly binding to the quaternary amines 
on the anion exchange resin.  
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 By loading the virus on a strong cation exchange resin, there was no strong flow rate 
dependency on infectious virus recovery in the eluted fractions indicating mass transfer played 
little to no role in the capture step to this resin.  Furthermore, these elution fractions contained 
significantly lowered amounts of contaminating protein and DNA with respect to input virus 
stocks.  Weak cation and anion exchangers may be used to further explore relative binding 
efficiency and recovery of virus preparations at different elution and loading conditions.  The 
details of enhanced binding to anion exhange resins may need to be explored further to elucidate 
the mechanism for reduced yields of infectious particles.  Thus, a more mechanistic description 
of virus charge-charge interactions would greatly aid the development of optimized purification 
protocols.  These results reflect progress towards optimal purification of the virus for large scale 
gene therapy applications while maintaining adherence to strict FDA requirements with respect 
to contaminating host cellular DNA and protein.     
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6.0  CONCLUSIONS 
HSV-1 remains an attractive vehicle for treatment of various neuropathies as well as a oncolytic 
vector.  Replication defective HSV-1 based gene therapy vectors are among the safest since they 
are missing most of the toxic IE genes necessary for viral replication.  Therefore, efficient 
manufacturing methods to produce these vectors are paramount for realizing their therapeutic 
potential.  Moreover, a basic understanding of host cell interactions with regard to genomic 
repression in different cellular environments will allow construction of more efficient vectors 
tailored to specific disease states.  Here, we have shown that the engineering of complementing 
cell lines can be optimized to provide high titer vector and purified to match FDA requirements 
by ion exchange chromatography.  We also demonstrate that the host cell interactions can be 
exploited to improve transgene expression from highly replication defective vectors in a 
repressive host cell environment.  The outcomes of this study are as follows. 
(1)  Improving the complementation profile of the essential immediate early gene can 
yield dramatic results with respect to viral yield.  The ICP0 promoter chosen for its 
inducibility in the context of infection was able to deliver ICP4 gene expression with 
faster kinetics leading to order of magnitude improvments in production of the highly 
replication defective vector JDTOZHE.  Likewise, this cell line was further optimized 
through the addition of the ICP0 gene and shown to grow the quadruple mutant 
JDQOZEH1 up to 1E6 PFU/ml. 
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(74)  A high throughput cell based chemical screen revealed a novel pathway that may 
lead to enhanced transgene expression in repressive cellular environments.  By inducing a 
more permissive cell state with the molecule 1 10 phenanthroline, enhanced EGFP from 
the viral backbone was readily observed.  The presence of a novel gene, SAG, was 
observed in the presence of this drug which implicates this function in allowing 
expression from the viral backbone.  Moreover, this gene was expressed consitutively in 
the permissive U2OS cell environment.  This is the first observation of this gene in this 
cell line which has implications in the field of oncology as well as virology. 
 
(3)  Ion exchange purification of HSV-1 was possible by cation exchange.  This strategy 
lead to pure stocks of virus with minimal contaminating protein and DNA.  By choosing 
the correct purification parameters such as pH, flow rate, and elution salt concentration 
high titers of this virus could be recovered.  This purification method is robust and 
amenable to scaleup which will have dramatic impacts as the pressure on manufacturing 
methods are increased to meet clinical demand. 
  In conclusion, the cell lines developed in chapter 3 will serve to aid in the growth an 
propagation of even more deleted vector backbones that have safer toxicity profiles.  These cell 
lines coupled with the use of ion exchange chromatography represent an efficient manufacturing 
platform for clinical grade replication defective HSV-1 based vectors.  The depression of HSV-1 
remains a mystery to the field of virology and the studies described in chapter 4 will aid in the 
field in that these interactions shed new light on the virus-host cell interactions in Vero cells as 
well as the enigmatic U2OS cellular environment.  
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